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Introduction
The isolation and discovery of the antimalarial activity of arte-
misinin 1 represents one of the great events in medicine in the
latter half of the 20th Century.[1] Artemisinin and its derivatives
dihydroartemisinin (DHA, 2), artesunate 3, and artemether 4[2–4]
are now widely used for treatment of malaria caused by the
most virulent parasite, Plasmodium falciparum.[5] The pivotal
problem in their use, that of a short pharmacological half-life,
was uncovered by the Chinese and countered early on by ad-
ministering artemisinin in combination with the pharmacologi-
cally robust mefloquine.[6] Consequently, artemisinins are now
routinely used in combination with longer half-life drugs,[7] and
emphasis is now placed on the development of fixed combina-
tions.
The results of Fe2+-induced decomposition of the clinically used
artemisinins, artemisone, other aminoartemisinins, 10-deoxoarte-
misinin, and the 4-fluorophenyl derivative have been compared
with their antimalarial activities and their ability to inhibit the
parasite SERCA PfATP6. The clinical artemisinins and artemisone
decompose under aqueous conditions to give mixtures of C radi-
cal marker products, carbonyl compounds, and reduction prod-
ucts. The 4-fluorophenyl derivative and aminoartemisinins tend
to be inert to aqueous iron(II) sulfate and anhydrous iron(II) ace-
tate. Anhydrous iron(II) bromide enhances formation of the car-
bonyl compounds and provides a deoxyglycal from DHA and en-
amines from the aminoartemisinins. Ascorbic acid (AA) acceler-
ates the aqueous Fe2+-mediated decompositions, but does not
alter product distribution. 4-Oxo-TEMPO intercepts C radicals
from a mixture of an antimalaria-active trioxolane, 10-deoxoarte-
misinin, and anhydrous iron(II) acetate to give trapped products
in 73% yield from the trioxolane, and 3% from the artemisinin.
Artemisone provides a trapped product in 10% yield. Thus, in line
with its structural rigidity, only the trioxolane provides a C radical
eminently suited for intermolecular trapping. In contrast, the
structural flexibility of the C radicals from the artemisinins allows
facile extrusion of Fe2+ and collapse to benign isomerization
products. The propensity towards the formation of radical
marker products and intermolecular radical trapping have no re-
lationship with the in vitro antimalarial activities of the artemisi-
nins and trioxolane. Desferrioxamine (DFO) attenuates inhibition
of PfATP6 by, and antagonizes antimalarial activity of, the aque-
ous Fe2+-susceptible artemisinins, but has no overt effect on the
aqueous Fe2+-inert artemisinins. It is concluded that the C radi-
cals cannot be responsible for antimalarial activity and that the
Fe2+-susceptible artemisinins may be competitively decomposed
in aqueous extra- and intracellular compartments by labile Fe2+ ,
resulting in some attenuation of their antimalarial activities. In-
terpretations of the roles of DFO and AA in modulating antima-
larial activities of the artemisinins, and a comparison with anti-
malarial properties of simple hydroperoxides and their behavior
towards thapsigargin-sensitive SERCA ATPases are presented. The
general basis for the exceptional antimalarial activities of artemi-
sinins in relation to the intrinsic activity of the peroxide within
the uniquely stressed environment of the malaria parasite is
thereby adumbrated.
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In contrast to the universal acceptance of the utility of arte-
misinins as the most potent and rapidly acting of all antimalari-
al drugs, a seemingly intractable controversy surrounds the
manner in which these drugs are presumed to act as parasitici-
dal agents. It has been proposed that activity arises as a result
of reductive or Fenton-like cleavage of the peroxide by Fe2+ to
generate alkoxyl radicals, which either abstract hydrogen
atoms from the artemisinin periphery or undergo b-scission to
provide carbon-centered radicals (C radicals) (Figure 1). The
C radicals are held to alkylate proteins vital to parasite func-
tion.[8–13] Formation of C radical intermediates in laboratory ex-
periments is demonstrated by interception with thiols[10] or
spin-trapping agents.[9, 14] C Radicals are purportedly involved in
the alkylation of the heme when ferrous heme is used to
induce cleavage of the peroxide in artemisinin and ana-
logues.[15,16] In the absence of trapping, the radical intermedi-
ates proceed to form stable end products, such as 14 and 15
from artemisinin (Figure 1 and below),[9, 17, 18] which thereby
serve as markers for the intercession of such radicals. The
products are at the same oxidation level as the starting artemi-
sinin; the Fe2+ cation acts as a catalyst, as it is regenerated
during their formation.[9] However, Fe2+ is considered to
engage in a second-order reaction with artemisinin under
aqueous conditions.[19] The results nevertheless are better inter-
preted in terms of a catalytic reaction, first-order in artemisinin,
being accelerated by the excess of the catalyst.
Whilst an artemisinin–heme interaction in one form or an-
other within the food vacuole of the malaria parasite has been
held responsible for antimalarial activity,[15,16] the ’heme theory’
itself is contentious. Artemisinins are vigorous inducers of CYP
enzymes[20] in which the iron in the heme prosthetic group
must cycle through the ferrous state in order to induce hy-
droxylation of the periphery of the molecule syn to the perox-
ide. This leaves the peroxide intact, as we first pointed out in
2001.[21] According to model studies, treatment of artemisinin
with ferrous heme generates an artemisinin C radical, which
undergoes an exceedingly rapid alkylation of the heme (of the
order of a bond vibration).[22] As ligand exchange is required to
free the putative C radical from the heme iron,[23] it cannot mi-
grate away from the heme, and exclusively provides a heme–
artemisinin adduct. Whilst the latter possesses antimalarial ac-
tivity, this tends to be in the micromolar range in in vitro
assays.[15,24] It has been suggested that the exogenously ap-
plied adduct may not readily permeate the vacuolar mem-
brane into the food vacuole.[15] Thus, this relatively weak activi-
ty may be ascribed to the redox properties of the ferric heme
nucleus within the adduct enhancing oxidative stress within
the cytosol of the parasite, as discussed below. Current data
tend to indicate that the site of action of artemisinins is not
within the food vacuole,[25] and it is established that artemisi-
nins do not inhibit hemozoin formation.[26] However, assertions
that artemisinins or artemisinin–heme adducts exert their ef-
fects by inhibiting hemozoin formation,[24] thereby allowing
buildup of ’toxic’ heme monomer in the food vacuole, or that
heme is both the ’activating agent’ and ’the target’ of artemisi-
nin continue to appear.[15,16] The detection of radiolabeled arte-
misinin within artemisinin–heme adducts in minor amounts in
urine or spleen extracts of infected mice administered with an
excess of artemisinin,[27] whilst indicating unambiguous al-
though minor sequestration of artemisinins by heme, are indi-
cative of routes of excretion of metabolites, and cannot be
taken at all as evidence of mechanism. Indeed, it is recognized
that competitive sequestration of artemisinins by heme, as
takes place in the foregoing experiment, attenuates their anti-
malarial activity.[28]
The idea that iron is required for activation of artemisinins
appears to rely in large measure on reports that iron chelators
such as desferrioxamine B (DFO) antagonize the antimalarial
activities of artemisinins in vitro.[29,30] DFO is a hydrophilic che-
lating agent with exceptional affinity for Fe3+ . The Fe3+ chelate
ferrioxamine B (FO) possesses a stability constant of 1031,
which is 1024 times greater than that of the Fe2+ chelate.[31] No-
tably, DFO is parasiticidal at a concentration of ~15 mm against
P. falciparum, a level which is about 60-fold lower than that re-
quired for a cytostatic effect against mammalian cells. DFO af-
fects late trophozoites and early schizonts, whereas artemisi-
nins are effective parasiticidal agents against the early ring
stage of the parasite. The antagonism cannot be reproduced
Figure 1. Fe2+-catalysed conversion of artemisinin 1 into “radical marker” products via seco C4 and C4 radicals held to be responsible for biological activity.
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in vivo.[32] Antagonism in vitro may arise by removal of the bio-
available or ’labile’ iron (as Fe3+) required for parasite metabo-
lism[33] or other effects.[34] FO is reduced by glutathione or as-
corbic acid under aqueous conditions, providing that an Fe2+
chelating agent is present.[35] DFO and FO markedly modulate
intracellular damage caused by peroxides,[36] DFO acts as a free
radical scavenger for hydroxyl and peroxyl radicals[37] and abol-
ishes the in vivo antimalarial activity of alloxan, a non-peroxidic
compound.[38] In relation to the basis of the antagonistic affect
of iron chelators towards artemisinin, it was earlier assumed
that iron chelators bind directly to heme to suppress activation
of the artemisinin.[15,29] As ferric heme is inert towards artemisi-
nin[17] and DFO displays exquisite specificity for Fe3+ , the pro-
posals that DFO associates with the ferrous heme required for
’activation’ of the artemisinin and that DFO ’abstracts’ Fe2+
from the heme[15] are implausible. An alternative explanation
proffered was that the alkylated heme adduct “tends to release
free iron”.[24] Release of iron from the adducts under physiolog-
ical conditions has not been demonstrated; the adducts are
stable, requiring forcing conditions to remove the iron.[39] The
inability of DFO to abstract Fe3+ from hematin has been dem-
onstrated,[40] and DFO has no effect on artemisinin–heme in-
hibition of erythrocyte membrane-bound ATPase activity.[41]
Our own survey on the decomposition of artemisinin 1 with
heme Fe2+ , free Fe2+ including Fe2+ generated by reduction
of Fe3+ in situ with cysteine, in aqueous and nonaqueous solu-
tions[17] coupled with a consideration of structure–activity rela-
tionships among artemisinin analogues, and the evident inabil-
ity of certain active antimalarial cyclic peroxides to generate
C radicals caused us to reject their feasibility as biologically sig-
nificant intermediates.[13,17, 21,42] More recently, we identified in-
consistencies between the reaction of artemisinins with ferrous
heme and their decomposition by free Fe2+ under aqueous
conditions.[43] Our work was criticized on the grounds that
some of the artemisinins, because of their presumed insolubili-
ty in the aqueous medium, cannot interact with the iron.[44] It
was demonstrated that one of our aqueous Fe2+-inert artemisi-
nins efficiently alkylated ferrous heme under aprotic condi-
tions, which are drastically different to those in the food va-
cuole of the parasite, the presumed site of “heme activation”
of the artemisinins.[23] However, 10-deoxoartemisinin 5
(Figure 2), which displays greater antimalarial activity than arte-
misinin, is rapidly decomposed by aqueous Fe2+ , but not by
aqueous ferrous heme,[23] and it has no effect on hemozoin for-
mation.[26]
Artemisinins, like the sesquiterpene thapsigargin (TG), are in-
hibitors of the malaria parasite sarco-/endoplasmic reticulum
Ca2+ (SERCA) ATPase.[45] Inhibition of SERCA orthologues of
P. falciparum (PfATP6), P. vivax (PvSERCA), and P. berghei
(PbSERCA) by artemisinins correlates with their ability to kill
these parasites.[46] Specificity appears to be associated with res-
idues lining the TG binding cleft of SERCAs, because altering a
single amino acid in transmembrane helix 3 through an L263E
mutation in PfATP6 decreases sensitivity to artemisinins.[46]
That a single substitution elsewhere in the PfATP6 sequence
segregates with the phenotype of increased IC50 for artemeth-
er in parasites from patients would appear to corroborate the
assignment of PfATP6 as a target for the artemisinins.[47] Arte-
misone 7 (Figure 2),[48] a representative of the class of 10-
amino-10-dihydroartemisinins,[43] in phase II trials cures malaria
patients at one third the dose of the clinically used artesunate
3.[49] Other aminoartemisinins such as 8 and 9 express excep-
tional activities in vivo against P. berghei in mice (sc ED90
values: 8, 0.6 mgkg1; 9, 0.35 mgkg1; artesunate 3,
7.2 mgkg1).[48] Artemisone is an especially effective inhibitor
of parasite SERCAs: Ki PfATP6 7, 1.70.6 nm (artemisinin 1,
16931 nm) ; Ki PvSERCA 7, 0.0720.012 nm (1, 7.7
4.9 nm).[46] Therefore, according to the Fe2+-activation model,
artemisone and the other aminoartemisinins are required to
generate C radicals which are especially adept at mediating
their biological activities, presumably by alkylating the ATP6
site.
Thus, the advent of artemisone, with its well-defined physi-
cochemical properties coupled with both its potent antimalari-
al activity and inhibition of PfATP6, provides a robust opportu-
nity to probe the relationship between its Fe2+-mediated de-
composition to putative C radicals and biological properties. 4-
Oxo-TEMPO efficiently reacts with radicals formed during Fe2+-
mediated decomposition of synthetic trioxolanes; the results
indeed have been used as a basis for design of new trioxolane
antimalarials.[50,51] Therefore, it is expedient to scrutinize this
construct by evaluating the ability of 4-oxo-TEMPO to trap the
putative C radicals from artemisone and other artemisinin de-
rivatives. We also examined the effects of DFO on PfATP6 in-
hibition and antimalarial activity
of the artemisinins of Figure 2,
and the effect of ascorbic acid
on the aqueous Fe2+-mediated
decomposition of the artemisi-
nin derivatives. Ascorbic acid an-
tagonizes in vitro antimalarial ac-
tivity of the clinically used arte-
misinins,[30,52] but it is also a
potent reductant for Fe3+ to
Fe2+ in aqueous solutions, even
where the former is associated
with normally stable Fe3+ che-
lates.[35, 53]
Figure 2. Artemisinins 1–12 and synthetic trioxolane 13[51] used in this study.
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Results
a. Ferrous iron mediated decomposition
i. Artemisinins 1–3
The decomposition of artemisinin 1, DHA 2, and artesunate 3
by ferrous sulfate in 1:1 acetonitrile/water at 20 8C during 24 h
(method a), although examined elsewhere,[9,17] was repeated
herein under milder conditions in order to provide a compari-
son of results with our artemisinins. Structures of products and
yields, including literature data from similar reactions conduct-
ed at 37 8C (method al),[9] are given in Table 1.
Ascorbic acid (method b) slightly enhanced the decomposi-
tion rates; reaction half-lives (Table 1) were determined from
plots of decomposition of artemisinin as a function of time. Ar-
temisinins 1 and 7 (below) were inert to an excess of ascorbic
acid in the absence of iron. An accelerating affect of ascorbic
acid on aqueous Fe2+-catalyzed reactions has not been report-
ed previously, although its presence apparently results in the
formation of minor amounts of other products.[18] DHA 2 with
FeBr2 in THF (method c)
[8–10,54] gave not the radical marker
products 16 and 17,[9] but rather the tricarbonyl compound 18
as a single epimer and the 2-deoxyglycal 19. At room tempera-
ture, 18 underwent conversion into a mixture containing 25%
of a second epimer. The same mixture was obtained by ther-
molysis of DHA at 100 8C.[55] A mixture of 18 together with an
isomer described as the C6 epimer was originally obtained by
thermolysis of DHA at 190 8C.[56] However, epimerization is
shown to occur at C1’ and not at C6.[55] The identity of 19 was
secured by dehydration of 2-deoxyDHA[2] with methanesulfonyl
chloride and triethylamine in dichloromethane. Ferrous acetate
in 1:1 acetonitrile/dichloromethane (method d), which effec-
tively induces decomposition of synthetic trioxolanes such as
13,[50,51] had little effect on DHA; approximately 72% was re-
covered, together with small amounts of the tricarbonyl com-
pound 18 and the furan 20.
ii. Artemisinins 5 and 6
Exposure of artemisinins 5 and 6 to ferrous sulfate/ acetoni-
trile/water gave the products and their yields as shown in
Table 2. Whereas 5 was efficiently decomposed, 6 is essentially
inert. Ascorbic acid accelerated decomposition of the former,
but had no effect on the latter. The tricarbonyl compound 26,
a single epimer, emerges as the dominant product from 5 at
the expense of the radical marker products 24 and 25 with
FeBr2/THF. The reagent has also been reported previously to
provide 26 and 28 from 5 (method cl, Table 2).[54] The tricar-
bonyl compound 26 was obtained as the sole product by
heating 5 at 100 8C (method e, Table 2). Compound 27, ob-
tained previously from 5 by a rearrangement driven by activa-
tion of the peroxide bridge by complexation with a Lewis
acid,[57] likely arises in the present case via a similar event trig-
gered by Fe2+ or Fe3+ . Ferrous acetate in 1:1 acetonitrile/di-
chloromethane gave the radical marker product 24 and the tri-
carbonyl compound 26.
iii. 10-Amino-10-dihydroartemisinins 7–12
With the exception of artemisone 7, the aminoartemisinins
tended to be relatively inert
under aqueous conditions
(Table 3). However, ascorbic acid
enhanced the decomposition of
the benzylpiperazine derivative
8 and had a slight effect on the
pyrimidylpiperazine derivative 9.
With FeBr2/THF, the derivatives
gave complex product mixtures
from which only relatively small
amounts of discrete decomposi-
tion products could be isolated.
The products include 2-deoxy-
DHA 35 from 8, tricarbonyl com-
pound 18, sulfamide
(H2NSO2NH2) from 10, and the
enamines 38 and 40 from the
primary amino derivatives 10
and 11. Identification of the en-
amines follows from a consider-
ation of their 1H and 13C NMR
data, the conversion of 38 by
ruthenium trichloride/sodium
periodate into the amide 41,
and identification by spectro-
scopic methods (Experimental
Section). The enamines 38 and
Table 1. Yields of products obtained from Fe2+-mediated decomposition of artemisinins 1–3.
Starting Artemisinin
R Group (Figure 2)
Method[a] Artemisinin Remaining
and Products [%]
Reaction
Half-Life [h]
1: artemisinin
R==O
a
al
b[b]
1: 31, 14 : 20, 15 : 26
1: 0, 14 : 25, 15 : 67
1: 11, 14 : 32, 15 : 32
15.4
7.3
2 : DHA
R=OH
al
c
d
2 : 0, 16 : 39, 17: 56
2 : 0, 18 : 57, 19 : 2
2 : 72, 18 : 4, 20 : 12
3 : artesunate
R=OOC ACHTUNGTRENNUNG(CH2)2COOH
a
al
b
3 : 6, 22 : 46, 23 : 22
3 : 0, 17: 25, 22 : 45, 23 : 23
3 : 2, 22 : 56, 23 : 22
6.3
4.3
[a] Method a) artemisinin (0.2–0.4 mmol), FeSO4 (0.3 equiv), MeCN/H2O (1:1), N2, 20 8C, 24 h; method al) from
Ref. [9]: artemisinin (2 mmol), FeSO4 (2 mmol), MeCN/H2O (1:1), N2, 37 8C, 24 h; method b) as for method a) +
ascorbic acid (AA, 1.0 equiv with respect to artemisinin); method c) artemisinin (0.8–1.0 mm), FeBr2 (0.5 equiv),
THF, N2, 20 8C, 45 min; method d) Fe ACHTUNGTRENNUNG(OAc)2 (1.5 equiv), MeCN/CH2Cl2 (1:1), N2, 20 8C, 24 h. [b] Other products
formed but not identified.
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40 represent a new structural
type. Their relationship with the
2-deoxyglycal 19 obtained from
DHA (Table 1) is brought out
below.
b. Radical interception with 4-
oxo-TEMPO
Attempts to intercept radicals by
treatment of 1:2 mixtures of
DHA 2 or the 10-aminoartemisi-
nin 11 and 4-oxo-TEMPO with
ferrous acetate in 1:1 acetoni-
trile/dichloromethane during
24 h at 20 8C according to the
method used to intercept radi-
cals from the trioxolane 13[51]
gave only variable amounts of
the products arising from the ar-
temisinins alone (cf. Tables 1 and
3). Treatment of a 1:2 mixture of
Table 2. Yields of products obtained from Fe2+-mediated decomposition of artemisinins 5 and 6.
Starting Artemisinin
R Group (Figure 2)
Method[a] Artemisinin Remaining
and Products [%]
Reaction
Half-Life [h]
5 : 10-deoxoartemisinin
R=H
a
b
c
cl
d
e
5 : 3, 24 : 42, 25 : 42, 26 : 4, 27: 2
5 : 0, 24 : 54, 25 : 40, 26 : 6
5 : 3, 24 : 13, 26 : 63, 27: 9, 28 : 9
5 : 0, 26 : 79, 28 : 8
5 : 1, 24 : 24, 26 : 20, 27:<2
5 : 17, 26 : 67
6.0
3.0
6
R=p-fluorophenyl
a
b
c[b]
6 : 96, 29 : <1, 30 : 2, 31: 2
6 : 94, 29 : <1, 30 : 4
6 : 17, 29 : 14, 31: 17
>24
>24
[a] Method a) FeSO4 (0.3 equiv), MeCN/H2O (1:1), N2, 20 8C, 24 h; method b) as for a + ascorbic acid (AA,
1.0 equiv) ; method c) FeBr2 (0.5 equiv), THF, N2, 20 8C, 45 min; method cl) from Ref. [53]: FeBr2 (1.94 equiv), THF,
N2, 20 8C, 15 min; method d) FeACHTUNGTRENNUNG(OAc)2 (1.5 equiv), MeCN/CH2Cl2 (1:1), N2, 20 8C, 24 h (cf. Ref. [51]) ; method e) 5
(neat solid), 100 8C, N2, 18 h. [b] Other products formed but not characterized.
Table 3. Yields of products obtained from Fe2+-mediated decomposition of 10-aminoartemisinins 7–12.
Starting Artemisinin
R Group (Figure 2)
Method[a] Artemisinin Remaining
and Products [%]
Reaction
Half-Life [h]
7: artemisone
R=4’-(S,S)-dioxo-thiomorpholin-1’-yl
a
b
c[b]
d[b]
7: 14, 18 : 5, 20 : 16, 33 : 28
7: 3, 18 : 6, 20 : 14, 33 : 20
7: 0, 18 : 22, 20 : 29, 34 : 9
7: 0, 18 : 3, 20 : 11, 32 : 12, 33 : 8
9.6
3.1
8
R=4’-benzylpiperazin-1’-yl
a
b
c
8 : 96, 18 : ~1, 20 : 3
8 : 29, 18 : 12, 20 : 27
8 : 0, 18 : 26, 20 : 26, 35 : 24
>24
9
R=4’-(1’’,3’’-pyrimid-2’’-yl)piperazin-1’-yl
a
b
9 : 97, 18 : ~1, 20 : 2
9 : 68, 18 : 2.5, 20 : 12
>24
10
R=NHSO2NH2
a[b]
c[b]
10 : 48, 18 : 2, 36 : 8
10 : 0, 18 : 32, H2NSO2NH2: 63
11
R=NH-p-fluorophenyl
a
c[b]
d[b]
11: 61, 37: 27
11: 0, 18 : 24, 38 : 12
11: 61, 37: 2, 38 : 1
12
R=NHCH2-p-fluorophenyl
c[b] 12 : 0, 18 : 5, 39 : 5, 40 : 24
[a] Method a) FeSO4 (0.3 equiv), MeCN/H2O (1:1), N2, 20 8C, 24 h; method b) as for a + ascorbic acid (AA, 1.0 equiv) ; method c) FeBr2 (0.5 equiv), THF, N2,
20 8C, 45 min; method d) FeACHTUNGTRENNUNG(OAc)2 (1.5 equiv), MeCN/CH2Cl2 (1:1), N2, 20 8C, 24 h. [b] Other products formed (5%) but not characterized.
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10-deoxoartemisinin 5 and 4-oxo-TEMPO with ferrous acetate
(1.5 equiv) gave the radical-trapped product 42 (3%), and the
products of Table 2. Artemisone provided the product 43 in
10% yield. Treatment with ferrous acetate (3 equiv) of a 1:1:2
mixture of 5, 13, and 4-oxo-TEMPO provided 42 (3%) and 44
(73%) arising by entrapment of the seco-radical 45 from 13.[51]
Thus, the inability of 4-oxo-TEMPO to intercept significant
amounts of C radicals from the artemisinins is not due to an
experimental artifact. Identification of 42 follows through a
consideration of its spectroscopic data and general similarity
with that of 24 (Table 2). Compound 43 is characterized
through its spectroscopic data (Experimental Section). In par-
ticular, the 1H NMR spectrum indicates a cis-coupling of 2.9 Hz
between H-10 and H-9. The genesis of this compound is dis-
cussed below.
c. Effect of desferrioxamine on biological properties
The effect of iron on PfATP6 inhibition was evaluated with des-
ferrioxamine B (DFO) (Figure 3). Although DFO attenuates in-
hibition of PfATP6 by artemisinin
1 (500 nm),[45] ascorbic acid (AA)
countered the effect of DFO, al-
though AA alone had no effect
on inhibition. Inhibition of
PfATP6 by artesunate 3 (250 nm)
and 10-deoxoartemisin 5
(100 nm), both rapidly decom-
posed by aqueous Fe2+ (Tables 1
and 2), was attenuated by DFO.
In contrast, DFO did not signifi-
cantly suppress inhibition by the
p-fluorophenyl derivative 6
(250 nm), artemisone 7 (5 nm),
and the pyrimidylpiperazine de-
rivative 9 (100 nm) (Figure 3).
Significantly, compounds 6 and
9 are inert to aqueous Fe2+ .
The effect of DFO on antima-
larial activity (Figure 4) displays a
provocative parallel with that on PfATP6 inhibition. DFO antag-
onized the antimalarial activities of the aqueous Fe2+-suscepti-
ble artesunate 3 and 10-deoxoartemisinin 5, although it had
no observable effect on the aqueous Fe2+-resistant p-fluoro-
phenyl derivative 6 or on artemisone 7.
The inhibition constant (Ki) for artesunate 3 against PfATP6
of 59.27.3 nm and the IC50 value of 63 nm against P. falci-
parum (3D7) represents an approximate 10-fold difference in
inhibitory potencies. Artemisone 7, with Ki=1.680.63 nm
and an IC50 value of 0.60.22 nm, demonstrates the smallest
Figure 3. Inhibition of PfATP6 by artemisinins (drug concentrations between
EC50 and EC90, black columns) and effect of desferrioxamine (DFO, 100 mm,
gray columns) (data for artemisinin 1, 500 nm, from Ref. [45]). Effect of ascor-
bic acid (AA, 100 mm, stippled column) on inhibition of PfATP6 by 1, and
effect of a mixture of AA and DFO (each 100 mm, diagonals) in restoring in-
hibition of PfATP6 by 1; inhibition of PfATP6 by artesunate 3 (500 nm) and
10-deoxoartemisinin 5 (100 nm) and attenuation by DFO (100 mm, p<0.001) ;
inhibition of PfATP6 by 4-fluorophenylartemisinin 6 (250 nm, p=0.8) and ar-
temisone 7 (5 nm, p=0.26) and relative lack of effect of DFO (p>0.05). DFO
has little effect on inhibition of PfATP6 by the pyrimidylpiperazine derivative
9 (100 nm, p=0.6). Data (meanSEM) are from 6–10 experiments, except
for 6 (n=3); effects of DFO are assessed with Students (unpaired) t test.
Figure 4. Isobologram analyses of the effect of desferrioxamine B (DFO) on antimalarial activities of artemisinins
against P. falciparum 3D7: a) DFO and 10-deoxoartemisinin 5 (*), DFO and artemisone 7 (~) ; b) DFO and artesu-
nate 3 (*), and DFO and 4-fluorophenylartemisinin 6 (~). The solid lines represent isoboles at which the drugs act
independently and additively. Data points above these lines indicate antagonism. After determination of IC50
values (within 48 h of adding antimalarials/inhibitors), fixed ratios of DFO to that of the artemisinin were used;
these ratios are: 10:0, 9:1, 7:3, 5:5, 3:7, 1:9, 0:10. The middle concentration of the inhibitors (5:5) approximates
the IC50 value of each inhibitor. The molar ratios of each inhibitor were calculated and the IC50 values of the mix-
tures presented in relation to the IC50 of the individual inhibitors.
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discrepancy (threefold).[46] However, the Ki value of 27739 nm
for 4-fluorophenylartemisinin 6 against PfATP6 is almost 200-
fold higher than its corresponding IC50 value (1.440.28 nm,
3D7). Compound 6 is highly lipophilic (logP 5.59; cf. artemi-
sone 7, logP 2.08) and is insoluble in water (<1 mgL1; cf. ar-
temisone 7, 89 mgL1).[49] Therefore, competitive partitioning
of 6 into the membrane lipids constituting the expression
system used for the oocyte SERCA assays[58] will occur, decreas-
ing the concentration of 6 available for binding. In contrast, se-
lective concentration of artemisinins takes place in infected er-
ythrocytes[59] wherein the more lipophilic artemisinins express
very good activities in vivo against the malaria parasite.[48]
Antimalarial activity of some of the artemisinins examined
herein are given in Table 4. According to this and other in vitro
and in vivo data,[48] artemisone 7 ranks among the most active
of all peroxidic antimalarials.[50] Trioxolane 13 possesses an IC50
value of 4.5 nm against the K1 strain.[50,51]
Discussion
a. Products of Fe2+-mediated decomposition
Before focusing on the wider implications of these results, we
subdivide the products into type a arising via Fenton-like
cleavage of the peroxide by Fe2+ and intramolecular closure of
the resulting C radicals with extrusion of Fe2+ (cf. Figure 1),
type b arising via formal peroxide cleavage and loss of formic
acid,[55] and type c arising via reduction (Figure 5). Formation of
products aiii is favored by aqueous conditions, and products b
and c by anhydrous conditions, becoming predominant for
DHA 2 (Table 1) and for 5 and 6. Product types aii and bi arise
from artemisinins bearing a leaving group at C10. Products a
are formed in significant amounts under aqueous conditions
from artemisinins 1–3, 5, and 7. The other aminoartemisinins
tend to be less amenable to decomposition under aqueous
conditions. In general, ferrous acetate under anhydrous condi-
tions was relatively ineffective, and of the artemisinins exam-
ined, only 5 and 7 provided appreciable amounts of products.
DHA 2 and the anilino artemisinin 11 are essentially inert.
The mode of formation of decomposition products has been
exhaustively discussed,[9,10, 17,18,54] and we confine our attention
here to the products arising from the aminoartemisinins 7–12
(Figure 6). When the decomposition provides intermediates 46
and 48 with a leaving group attached either directly to C10 as
in 46 (formate), or via an electronically connected framework
as in 48 (acetate), the amino group induces fragmentation to
give the iminium ions 47 and 49, which will undergo hydroly-
sis to the carbonyl compounds on workup of the reaction mix-
ture. In the case of the sulfamido artemisinin 10, the amine
product of hydrolysis, the insoluble sulfamide (H2NSO2NH2) is
recovered. The formation of the radical-trapped product 43 di-
verts the seco-C4 radical away from the furan-forming pathway
leading to 48. Entrapment with 4-oxo-TEMPO is followed by
extrusion of acetate and Fe3+ , and intramolecular cyclization of
the pendant hydroxyl with the iminium group in intermediate
50 to give 43. This has the interesting consequence that the
overall reaction will no longer be catalytic in Fe2+ . Formation
of the trapped product 42 from 10-deoxoartemisinin, which
contains no electrofugal group, is consistent with the proposal
of Figure 6. The pathway leading via the C4 radical and epox-
ide 51 is disfavored under nonaqueous conditions; the infer-
ence is that the incipient O2 radical prefers to undergo cleav-
age to provide the tricarbonyl compound 46, a premise which
is consistent with a non-concerted cleavage of peroxides to
provide carbonyl compounds.[54,55] The alternative pathway to
the carbonyl compounds involves an Fe2+- (or Fe3+-) mediated
heterolytic decomposition of the peroxide, formally a [2+2+2]
cycloreversion, for which the thermal counterpart is demon-
strated in the thermal decomposition of 10-deoxoartemisinin 5
(Table 3).
The formation of the products c may proceed via reduction
of a hydroperoxide intermediate arising via ring opening[21]
and re-closure of the resulting alcohol.[60] Ring opening of DHA
to the hydroperoxide 52 (X=H, Y=O, Figure 7) is implicated
in the facile formation of a rearranged peroxyhemiacetal from
DHA.[55] In the present case, ring opening of DHA and the arte-
misinins 11 and 12 may be driven by protonation of the perox-
ide or by complexation with Fe2+ . The hydroperoxides 52 on
Table 4. In vitro inhibition data for artemisinins against W2 (chloroquine-
resistant) and D10 (chloroquine-sensitive) strains of P. falciparum.
Compd[a] IC50 [nm] Compd
[a] IC50 [nm]
W2 D10 W2 D10
1 4.820.48 7.332.21 9 1.530.51 2.040.49
5 1.710.10 3.390.71 10 3.030.98 7.892.94
7 0.600.25 0.720.24 11 0.820.39 2.071.73
8 0.660.27 1.170.86
[a] See Figure 2 for structures.
Figure 5. Product types obtained from Fe2+-catalysed conversion of artemisinins: a, ’radical marker’ products (cf. Figure 1) ; b, cleavage products ; c, reduction
products.
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reduction give the corresponding alcohol, which close to the
2-deoxyartemisinins ci. Alternatively, closure of the alcohols
arising via reduction of 52 via the corresponding enol or en-
amine intermediates provide the enol and enamine products
19, 38, and 40.
b. Ramifications for antimalarial mechanism of action
i. Fe2+-mediated decomposition and C radicals
Artemisone 7 does not provide significantly greater amounts
of radical marker products a (Figure 6) than does artemisinin 1,
even though inhibition of
PfATP6 and antimalarial activity
are vastly superior. In general,
the aminoartemisinins are more
refractory to reduction by aque-
ous Fe2+ than other artemisinins.
The propensity of artemisinins to
undergo decomposition is not
related to aqueous solubility. Al-
though artemisinins 5 and 11
have aqueous solubilities of 294
and 295 mgL1 at pH 7.2, the
former is almost completely de-
composed by aqueous Fe2+ , and
the latter is substantially more
inert. Artemisone 7, with an
aqueous solubility of 89 mgL1, is more rapidly decomposed
than artemisinin 1, with a solubility of 63 mgL1. The benzylpi-
perazine derivative 8, with an aqueous solubility of 8 mgL1 is
essentially inert to aqueous Fe2+ , but ascorbic acid enhances
the decomposition.
It is clear that under either aqueous or anhydrous condi-
tions, Fe2+ encumbered with oxygen ligands is less active as a
decomposition catalyst than are ferrous halides.[9, 10,17, 43,61] The
rate-determining step is displacement of the ligand, more
facile for halide, by peroxide, to form a complex in which
inner-sphere electron transfer from Fe2+ to the peroxide ini-
tiates the Fenton-like cleavage.[62] The amino groups of the 10-
Figure 6. Pathways proposed for the formation of products from aminoartemisinins 5–7 and radical-trapped product 43 from artemisone 7.
Figure 7. Proposal for the formation of dehydroglycal 19 from DHA 7 and enamines 38 and 40 from DHA and pri-
mary aminoartemisinin derivatives 11 and 12.
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aminoartemisinins will associate with Fe2+ to form complexes
that may either slow the rate of decomposition, or for steric
reasons hinder formation of the complex between Fe2+ and
the peroxide.[48] The enhanced decomposition of the benzylpi-
perazine and pyrimidinylpiperazine derivatives 8 and 9 in-
duced by ascorbic acid may be due to competitive generation
of an ascorbic acid–Fe2+ complex[63] that reduces the peroxide.
Be that as it may, on the basis of the C radical hypothesis, the
acceleration of the aqueous Fe2+ decompositions by ascorbic
acid is out of key with the antagonism of antimalarial activities
reported for this reagent,[30,52] given that the (faster) reactions
leading to the radical marker products a imply an enhanced
flux of ’bioactive’ C radical intermediates.
The radical center in the seco-radical 45 from trioxolane 13,
embedded in a rigid hydrocarbon skeleton, is amenable to effi-
cient intermolecular trapping to provide 44. In contrast, the
formation in poor yields of radical-trapped products 42 and 43
from artemisinins 5 and 7 indicates that internal quenching of
the structurally relatively complex and flexible seco-C4 radical
intermediates (cf. Figures 1 and 6) via extrusion of Fe2+ to pro-
vide products ai–ii is facile. In addition, generation of the arte-
misinin C radicals competes with Fe2+-mediated cleavage of
the peroxide to provide carbonyl compounds b (cf. Figure 6), a
decomposition pathway which is not available to trioxolane
13. That is, the intercession of this manifold of intramolecular
decomposition pathways of the artemisinins triggered by Fe2+
implies that the concentration of the C radical intermediates
available for an intermolecular reaction with a crucial biomole-
cule will be low indeed, even in the situation where the arte-
misinin may be bound in a protein cleft, such as the TG-sensi-
tive cleft of PfATP6. This factor aside, we have already pointed
out[13] that those elegantly constructed analogues of artemisi-
nins lacking C3 and/or C4,[64] and a rearrangement product of
DHA, which is incapable of reverting to DHA,[42,55] are active an-
timalarials, even though formation of C radicals are not appar-
ent for these substrates.
In light of the foregoing, the recent idea[65] that products of
type ai may be taken as markers of the biological importance
of the seco-C4 radical precursors (cf. Figures 1 and 6) is note-
worthy. The formation of these compounds in limited yields
under aqueous conditions, and the inability to effectively trap
the C radical precursor with the optimal, although non-biologi-
cal reagent—the stable radical 4-oxo-TEMPO—implies that in
the intracellular environment, the likelihood of the C radical
precursor damaging a vital biomolecule by whatever mecha-
nism must be small. Finally, the successful trapping of C radical
45 by the stable O-centered radical cannot be used to support
the assumption that such C radicals are the actual cytotoxic in-
termediates in biological systems. C Radicals associated with a
saturated flexible framework are unsuited per se for alkylation
of biomolecules.[13] Suffice it to say that they are reduced by
thiols, as has been recorded in the artemisinin area,[10,18] and
react at a diffusion-controlled rate with oxygen. An inference
that such radicals may react with oxygen has been made.[61]
C Radicals are generated by treatment of oxaziridines with
Fe2+ , yet the compounds are either inactive or feebly active as
antimalarials.[66]
ii. Interpretation of the effects of Fe2+ , ascorbic acid, and DFO
on biological properties
The observations recorded herein, namely that ascorbate accel-
erates the decomposition and that DFO antagonizes the
PfATP6 binding and antimalarial activities of the aqueous Fe2+-
susceptible, but not that of the aqueous Fe2+-insusceptible ar-
temisinins, are not easily reconciled with current dogma on
the mechanism of action of artemisinin antimalarials. Further-
more, if the C radicals are not viable intermediates, then, if it is
accepted that an interaction of the artemisinin with PfATP6 is a
prerequisite to parasite death, a different kind of reactive inter-
mediate from the artemisinin which irreversibly modifies the
transporter or destroys a crucial endogenous substrate, such
as a cofactor associated with the transporter, must be in-
volved.
The Fe2+ available for activation of the artemisinins within
the parasitized erythrocyte is presumed to be associated with
the extra- and intracellular labile iron pools containing redox-
active iron complexes, which are subject to scavenging by che-
lators, and which are responsible for mediating generation of
reactive oxygen species (ROS) and modulating oxidative
stress.[67,68] Thus, those artemisinins 1, 3, and 5 susceptible to
aqueous Fe2+-mediated decomposition may suffer competitive
degradation in the aqueous extracellular medium or intracellu-
lar aqueous cytosolic compartments by the labile Fe2+ . The an-
tagonism of antimalarial activity by ascorbic acid is then ascri-
bed to the greater concentrations of Fe2+ generated by ascor-
bic acid enhancing this degradation. DFO both attenuates
PfATP6 inhibition by the aqueous Fe2+-susceptible artemisinins
and antagonizes their antimalarial activities, but has relatively
little effect on the aqueous Fe2+-resistant artemisinins 6 and 9.
This observation is not easily explained. However, DFO, via the
Fe3+ complex ferrioxamine (FO), likely sequesters and concen-
trates iron stores, probably in aqueous compartments in the
cytosol.[35] Exposure to an endogenous reductant such as glu-
tathione or ascorbate[35] may produce locally high concentra-
tions of Fe2+ that competitively destroy the susceptible artemi-
sinins, but have little effect on the aqueous Fe2+-inert artemisi-
nins 6 and 9. Ascorbic acid neutralizes the attenuating effect
of DFO on inhibition of PfATP6 by 1 (Figure 3) because Fe3+ is
no longer available for sequestration by DFO. Alternatively, ar-
temisinins may undergo ring opening to provide free hydro-
peroxides (cf. 52, Figure 7) in the intracellular environ-
ment.[17, 21,42,60] Such ring opening of artemisinin and DHA, the
principle metabolite of the clinically used artemisinins artesu-
nate 3 and artemether 4, occurs under mild conditions in the
laboratory,[55,60] although this has yet to be demonstrated for
artemisinins bearing other groups at C10. In any event, ascor-
bate, DFO, or endogenous reductant in the aqueous intracellu-
lar environment will destroy the hydroperoxides derived from
the aqueous soluble artemisinins, decreasing the amount of
drug available for a parasiticidal effect.
Irrespective of the exact mode of attrition, 10-deoxoartemisi-
nin 5, with an aqueous solubility of 294 mgL1, is highly sus-
ceptible to decomposition by aqueous Fe2+ , and DFO attenu-
ates its inhibition of PfATP6 and antagonizes antimalarial activi-
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ty. Artemisone 7, with its good physicochemical properties, is
efficiently transferred to the target,[46] and the effect of DFO is
less pronounced. The fluorophenyl derivative 6 and aminoarte-
misinins such as 8 are not readily decomposed by aqueous
Fe2+ ; that is, they cannot suffer competing degradation en
route to the target. Thus, DFO does not overtly influence bind-
ing to PfATP6 or antimalarial activities of these compounds. It
is of interest to note that 6 and other lipophilic aminoartemisi-
nins generally display greater antimalarial activities (and higher
toxicities) than do more polar derivatives.[4, 43,48] These com-
pounds will be less prone to enter the aqueous cellular com-
partments and will localize and migrate within lipophilic struc-
tures such as organelle membranes; that is, they are protected
from adventitious decomposition. In common with the action
of lipophilic hydroperoxides, biological activities will not be
greatly impaired by the presence of iron chelators, which are
unlikely to access iron in a lipophilic environment.[69]
The antimalarial activities and their modulation by DFO, and
the effect of artemisinins on the thapsigargin (TG)-sensitive
SERCA ATP6 target have an intriguing parallel with the biologi-
cal properties of structurally simple peroxides that cannot
readily generate C radicals. This parallel in antimalarial activities
has been brought out in a classical review of oxidant drugs
and malaria.[70] tert-Butyl hydroperoxide (TBH) induces rapid re-
duction in parasitemia in mice infected with P. vinckei, whereas
it has no effect on uninfected mice,[71] and is parasiticidal in vi-
tro towards P. falciparum.[72] In relation to its effect on Ca2+
transporters, TBH increases intracellular Ca2+ levels in PC12
pheochromocytoma cells. Pretreatment with TG abolishes the
effect of TBH, whereas pretreatment with TBH abrogates the
TG-induced increase in Ca2+ .[73] Hydrogen peroxide at micro-
molar concentrations is parasiticidal in vitro and in vivo against
P. yoelii and in vitro against P. falciparum.[70] The effect of H2O2
in modulating intracellular Ca2+ levels is well known.[74] As one
pertinent example, it increases cytosolic and mitochondrial
Ca2+ concentrations in pancreatic cells ; pretreatment with TG
inhibits the H2O2-induced changes. Thus, H2O2, like TBH, exerts
an effect on TG-sensitive Ca2+ ATP transporters in mammalian
cells.[75] Artemisinins at micromolar levels induce apoptosis in
mammalian cells by modulating cytosolic Ca2+ levels, although
the direct cause has yet to be pinpointed.[76] To summarize, the
hallmark of oxidant stress as elicited by all peroxidic com-
pounds is overt modulation of intracellular Ca2+ flux[77] leading
to apoptosis, such as may be effected by inhibition of the TG-
sensitive ATP transporter PfATP6 in the parasite.
Thus, a proper appreciation of the manner in which artemisi-
nins, and apparently simple hydroperoxides, interact with the
transporter becomes crucially important. In this respect, it is
unclear how structurally diverse peroxides such as 10-deoxoar-
temisinin 5, the pyrimidinylpiperazine derivative 9, trioxolane
13 and its close relatives,[50,78] and a steroidal tetroxane,[79]
which possess antimalarial activities in vitro ranging from 1.5–
11.4 nm may bind into the TG cleft to inhibit parasite PfATP6.
For example, the trioxolane, OZ OZ277 (RBx6660) is two orders
of magnitude less effective in inhibiting PfATP6 (Ki=7700 nm)
than is artemisinin (Ki=79 nm), an interaction which is also ap-
parently sensitive to DFO.[78] Compounding this quandary are
the observations that replacement of residues lining the TG
binding cleft in PfATP6 by orthologous residues affects the in-
hibition by artemisinin and artemisone, and that mammalian
SERCAs are at least an order of magnitude less sensitive to
these artemisinins.[46] Although artemisinin reduces mitochon-
drial inner membrane potential in a yeast model through iron-
dependent generation of ROS,[80] it is unlikely our Fe2+-resist-
ant artemisinins will elicit such an effect. The non-neurotoxic
artemisone 7, unlike artemether or DHA, has no effect on mito-
chondrial membrane potential, on ROS levels, or on inhibition
of the respiratory chain in neuronal cell lines.[81] Therefore, the
proposal that artemisinins exert their antimalarial activity by in-
terfering with mitochondrial function[80] is premature.
Conclusions
The PfATP6 inhibition and antimalarial mechanism is independ-
ent of reductive cleavage of the peroxide by Fe2+ leading to
C radicals.[12] The potent antimalarial activities of our aminoar-
temisinins are inconsistent with their demonstrably inefficient
conversion into C radicals, which further, because of facile in-
tramolecular quenching pathways, cannot be fruitfully inter-
cepted. In contrast, the trioxolane 13 provides a good yield of
a radical-trapped product, yet possesses lower antimalarial ac-
tivity (higher IC50 value). As an explanation for the antimalarial
activity of artemisinins, or indeed of the biological activities of
artemisinins at large, the C radical hypothesis is not feasible.
Artemisinins, trioxolane, and tetroxane analogues, as perox-
ide carriers, are capable of drastically influencing intracellular
events, as has been established for hydrogen peroxide and
alkyl hydroperoxides. As artemisinins have the peroxide encap-
sulated within a robust tricyclic scaffold, they are less prone to
undergo adventitious decomposition such as reduction or
Haber–Weiss chemistry characteristic of unprotected hydroper-
oxides. If binding to PfATP6 is a crucial step in the pathway to
destruction of the malarial parasite, it needs to be established
if this is associated with an irreversible chemical change in the
cleft, or destruction of a crucial endogenous substrate such as
a cofactor, which occurs because of the binding, and which
has the consequence of inhibiting overall function of the trans-
porter. The precise role of the peroxide remains to be defined.
If an open hydroperoxide is involved, it can act as an electro-
philic oxygenating agent, or provide hydroxyl or alkoxyl radi-
cals now capable of reacting with biological sub-
strates.[17,21, 43,60] It should be noted that the intercession of the
Haber–Weiss chemistry leading to O-centered radicals is not
necessarily dependent on the presence of metal ions.[82] Alter-
natively, the hydroperoxide or the intact peroxide may act as
an electron acceptor (oxidant), for example, in disrupting a cat-
alytic cycle involving the cofactor.[83] The important difference
here is that it is the intrinsic reactivity of the peroxide which
confers antimalarial activity, not the erratically derived and
fickle C radicals.
The intraerythrocytic malaria parasite is in an environment
which is oxidatively stressed.[70,83,84] Thus, enhanced levels of
methemoglobin, of lipid peroxidation, increased intracellular
flux of hydrogen peroxide and ROS, and other effects render
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intraerythrocytic parasites peculiarly susceptible to modulation
of oxidative stress. Substantially lower quantities of artemisi-
nins—on the order of nanomolar concentrations—are required
to kill the intraerythrocytic parasite, whereas oxidatively un-
stressed mammalian cells require larger amounts of artemisi-
nins—in the micromolar range—to elicit cytotoxic effects.[65,85]
Fe2+ profoundly modulates oxidative stress in its own
right.[67, 86] Thus, the enhancement of cytotoxicities of artemisi-
nins in mammalian cells[87] by addition of Fe2+ is unsurprising.
At the proof stage of this manuscript, a publication ap-
peared presenting details of an examination of the effects of
DFO and the more lipophilic chelator deferiprone on the anti-
malarial activities of a series of peroxidic antimalarials.[88] The
chelators were shown to antagonize the antimalarial activities
of selected peroxides, including artemisone. It is important to
note that the “antagonism” does not mean destruction of anti-
malarial activity. The drugs are still substantially antimalarial
active in the presence of the chelators; therefore, extrapolation
of the authors’ interpretation of the role of the chelators im-
plies that there must be a “non-iron” pathway of activation.
The possibility of the chelators reacting with the artemisinins
or putative peroxide intermediates aside, if one function of the
chelators is to remove labile iron, this will alleviate oxidative
stress, and more of the artemisinin is now required to kill the
parasite, as explained in the preceding paragraph. Thus the
data in reference [88] , including the use of normal nonprolifer-
ating human PBMC as a control, do not imply at all that per-
oxidic antimalarials have to react chemically with iron to exert
their antimalarial effect.
Experimental Section
Artemisinin 1 and DHA 2 were purchased from the Kunming Phar-
maceutical Corporation (PR China) or from Haphacen, Hanoi Col-
lege of Pharmacy (Vietnam) and used without further purification.
Artesunate 3 was prepared according to the Chinese procedure.[3]
The other derivatives were prepared as previously described.[43,48]
4-Oxo-TEMPO (2,2,6,6-tetramethyl-1-piperidinyloxy, free radical)
was used as received from Sigma–Aldrich.
All reactions were carried out under an atmosphere of N2. The fol-
lowing solvents were dried prior to use: ethyl acetate from MgSO4,
hexanes (CaCl2), CH2Cl2 (CaH), triethylamine (CaH and stored over
KOH pellets), and tetrahydrofuran (sodium in benzophenone). TLC
was performed with Merck Kieselgel 60 F254 plates and visualized
with UV light (254 nm) and/or heating after treatment with 5%
ammonium molybdate in 10% concentrated H2SO4. Column chro-
matography was performed with Merck silica gel 60 (0.04–
0.063 mm). 1H and 13C NMR spectra were obtained as solutions in
CDCl3 on a Varian Mercury spectrometer operating at 300 and
75 MHz, respectively. Melting points were carried out on a Leica
Hot Stage DME E compound Microscope and are corrected. MS
data were obtained on a Finnigan TSQ 7000 mass spectrometer
(CI+ , methane), on an API QSTAR high-performance triple-quadru-
pole time-of-flight (ToF) mass spectrometer with electrospray ioni-
zation, and on a Waters Micromass GCT premier ToF high-resolu-
tion mass spectrometer (CI+ , methane). IR spectra were recorded
either on a PerkinElmer PC 16 or a PerkinElmer Spectrum One
spectrometer. Optical rotations were performed on a PerkinElmer
model 241 spectrometer. Elemental analyses were obtained from
MEDAC Ltd., Surrey (UK).
1) In vitro decomposition of artemisinin derivatives with Fe2+
salts
a) FeSO4 : A solution of FeSO4·7H2O (33.2 mg, 0.3 equiv) in deion-
ized H2O (4 mL) was added dropwise to a stirred solution of the ar-
temisinin derivative (0.4 mmol) in CH3CN (4 mL) under N2 at room
temperature, and the mixture was stirred for 24 h. It was then ex-
tracted with CH2Cl2 (3R20 mL) and the combined organic layer
was washed with deionized H2O (20 mL). The organic layer was
separated and dried (MgSO4). After filtration and concentration of
filtrate under reduced pressure, the amounts of unreacted starting
material and the products in the crude product mixture were esti-
mated by 1H NMR spectroscopy of the product mixtures as de-
scribed below. The components were also separated by chroma-
tography with ethyl acetate/hexanes as eluent to give the unreact-
ed artemisinin derivative and the decomposition products. Prod-
ucts were weighed and identified either by comparison with re-
ported data, or if new, by spectroscopic methods as described
below. Yields as given below refer to the amounts of starting mate-
rial and products isolated from the reaction mixture.
b) FeSO4–ascorbic acid : According to procedure a), a solution of
FeSO4·7H2O (33.2 mg, 0.3 equiv) and ascorbic acid (AA, 70.4 mg,
0.4 mmol, 1.0 equiv) in deionized H2O (4 mL) was added dropwise
to a stirred solution of the artemisinin derivative (0.4 mmol) in
CH3CN (4 mL). Products were either isolated or estimated by
1H NMR spectroscopy as described below.
a) and b) FeSO4 and FeSO4–ascorbic acid and reaction half-lives :
Set I : A solution of FeSO4·7H2O (74.7 mg, 0.3 equiv) in deionized
H2O (9 mL) was added dropwise to a stirred solution of the artemi-
sinin derivative (0.9 mmol) in CH3CN (9 mL) under N2 at room tem-
perature. Set II : A solution of FeSO4·7H2O (49.8 mg, 0.3 equiv) in de-
ionized H2O (6 mL) was added dropwise to a stirred solution of the
artemisinin derivative (0.6 mmol) in CH3CN (6 mL) under N2 at
room temperature. Aliquots (3.4 mL) of the reaction mixture were
withdrawn (at 2, 3, 4, 6, and 10 h for Set I, and at 14, 18, and 24 h
for Set II), followed by extraction with CH2Cl2 (3R10 mL), and the
organic layer in each case was washed with deionized H2O (10 mL).
The organic layer was separated and dried (MgSO4). After filtration
and concentration of the filtrate under reduced pressure, the resi-
due was taken into CDCl3 containing 1,3,5-trimethoxybenzene (~
5.0 mg) as an internal standard. 1H NMR measurements were con-
ducted by comparing the intensity of the aromatic signal in the
standard at 6.08 ppm against the singlet due to H-12 in each of
the artemisinins (artemisinin 1 5.86, artesunate 3 5.44, 4-fluoro-
phenyl 6 5.55, artemisone 7 5.27, benzylpiperazine derivative 8
5.35, pyrimidinylpiperazine derivative 9 5.27, sulfamide 10 5.38, 4’-
fluorophenylamino 11 5.41, 4’-fluorobenzylamino 12 5.27 ppm). As
an independent check, starting material was also isolated in a pure
state by chromatography, weighed, and constitution verified by
spectroscopic analysis. In the case of the 10-deoxo compound 5,
the signal due to H-12 (5.20 ppm) overlaps the signal of H-12 in
the decomposition product 25 in the 1H NMR spectra of the prod-
uct mixtures. Therefore, the rate of decomposition of 10-deoxoar-
temisinin was followed by monitoring changes in peak intensities
of the signal due to the methyl group at C3 (1.48 ppm) and H-9
(multiplet at 2.65 ppm) relative to the internal standard. The de-
composition products were isolated by flash column chromatogra-
phy with 20% ethyl acetate in hexanes as eluent, weighed, and
each identified as described below. The procedure was repeated
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by running the decomposition reactions in the presence of ascor-
bic acid (1.0 equiv). Rates of decomposition of selected artemisi-
nins were plotted against time, and half-lives were obtained from
the plots.
c) FeBr2 : The artemisinin (1.1–1.4 mmol) and anhydrous FeBr2
(0.5 equiv) in THF under N2 were allowed to stir for 45 min at room
temperature. The reaction mixture was quenched with saturated
aqueous sodium hydrogen carbonate (100 mL). The aqueous layer
was extracted with ethyl acetate (3R30 mL). The organic layer was
separated and washed with saturated aqueous NH4Cl (3R30 mL).
The combined organic layer was dried (MgSO4). After filtration and
concentration of the filtrate under reduced pressure, the products
were separated by chromatography with ethyl acetate/hexanes as
eluent.
d) Fe ACHTUNGTRENNUNG(OAc)2 and 4-oxo-TEMPO : A solution of anhydrous Fe ACHTUNGTRENNUNG(OAc)2
(1.5 equiv) in CH3CN (8 mL) was added to a stirred solution of arte-
misinin derivative (1.3–2.0 mmol) and 4-oxo-2,2,6,6-tetramethyl-1-
piperidinyloxy (TEMPO, 2.0 equiv) in CH2Cl2 (8 mL) under N2 at
room temperature. After 24 h, the reaction mixture was quenched
with saturated aqueous sodium hydrogen carbonate (16 mL). The
aqueous layer was extracted with ethyl acetate (3R32 mL). The or-
ganic layer was separated and washed with saturated aqueous
NH4Cl (2R32 mL). The combined organic layer was dried (MgSO4).
After filtration and concentration of the filtrate under reduced
pressure, the products were separated by chromatography with
ethyl acetate/hexanes as eluent.
2) SERCA assay in oocyte preparations
Assays were conducted after microinjection of cRNA as previously
described.[89] Ca2+ ATPase activity was measured (pCa 5.5, 10 mg
total protein, 25 8C) using a coupled enzyme assay as described,
and Ki refers to apparent half-maximal inhibition of Ca
2+-depen-
dent ATPase activity. The effects of DFO (100 mm) on inhibition of
PfATP6 activity were assessed using concentrations of inhibitors
that are close to their Ki values.
3) Parasite culture and isobologram analysis
Parasites (clone 3D7, D10, and W2) were cultured using standard
techniques. IC50 values were determined within 48 h of adding an-
timalarials. For isobologram analyses (Figure 5), ratios fixed at 10:0,
9:1, 7:3, 5:5, 3:7, 1:9, and 0:10 of inhibitor A to that of inhibitor B
were used. The middle concentration of the inhibitors (5:5) was
aimed to be the IC50 of each drug. The molar ratios of each drug
were calculated, and the IC50 values of the mixtures presented in
relation to the IC50 of the individual drugs.
4) Decomposition of artemisinins
Artemisinin 1:
a) FeSO4 : Compounds 1 (34.8 mg, 31%), 14 (22.2 mg, 20%), and
15 (29.8 mg, 26%) were obtained from FeSO4·7H2O (33.2 mg,
0.3 equiv) and 1 (112.8 mg, 0.4 mmol) in CH3CN/deionized H2O (1:1,
8 mL) followed by chromatography with ethyl acetate/hexanes
(20:80); 14 colorless solid, mp: 92–94 8C (92–94 8C,[9] 91–92 8C[90]) ;
1H NMR: d=1.00 (d, J=6.2 Hz, 3H, 6-Me), 1.04–1.16 (m, 1H), 1.22
(d, J=7.0 Hz, 3H, 9-Me), 1.43–1.60 (m, 3H), 1.85–2.10 (m, 5H), 2.17
(s, 3H, MeCO), 3.13–3.22 (m, 1H), 3.95 (ddd, J=8.8, 8.2, 7.0 Hz, 1H),
4.22 (dd, J=9.4, 9.4 Hz, 1H), 6.63 ppm (s, 1H); 15 colorless solid,
mp: 200–201 8C (199–201 8C[9] , 190–192 8C[90]) ; 1H NMR: d=0.96 (d,
J=6.2 Hz, 3H, 6-Me), 0.98–1.19 (m, 2H), 1.22 (d, J=7.0 Hz, 3H, 9-
Me), 1.41–1.58 (m, 5H), 2.00 (s, 3H, 3-Me), 1.82–2.35 (m, 3H), 3.19–
3.26 (m, 1H), 3.63 (s, 1H), 5.63 ppm (s, 1H, H-12).
b) FeSO4–ascorbic acid : The above procedure was repeated with
ascorbic acid (70.4 mg, 0.4 mmol, 1.0 equiv) to provide 1 (12.6 mg,
11%), 14 (35.6 mg, 32%), and 15 (35.6 mg, 32%). Other products
were formed in smaller amounts, but were not characterized.
Dihydroartemisinin 2 :
c) FeBr2 : DHA (500 mg, 1.76 mmol) and FeBr2 (190 mg, 0.88 mmol,
0.5 equiv) in THF (15 mL) were stirred under a N2 atmosphere for
45 min. Afterward, the mixture was quenched with saturated aque-
ous sodium hydrogen carbonate (100 mL) and then extracted with
ethyl acetate (3R30 mL). The combined organic layer was then
washed with saturated aqueous NH4Cl. The aqueous layer was ex-
tracted with ethyl acetate (3R30 mL). The combined organic layer
was dried (MgSO4). Filtration and concentration of the filtrate
under reduced pressure left a pale-yellow residue, which on chro-
matography with ethyl acetate/hexanes (10:90) gave firstly the 2-
deoxyglycal 19 (9.5 mg, 2.2%) and the tricarbonyl compound 18
(238.4 mg, 57%) as an oil. No DHA was recovered. Recrystallization
of the 2-deoxyglycal 19 from ethyl acetate/hexanes gave colorless
bar-shaped crystals, mp: 103.5–104.5 8C; [a]22D =13.18 (c=0.63,
CHCl3) ;
1H NMR: d=0.92 (d, J=4.9 Hz, 3H, 6-Me), 1.03–1.39 (m,
3H), 1.47 (s, 3H, 3-Me), 1.62 (br s, 3H, 9-Me), 1.67–1.78 (m, 2H),
1.79–1.98 (m, 3H), 2.35–2.45 (m, 1H), 5.58 (s, 1H, H-12), 6.04–
6.05 ppm (q, 1H, J=1.2 Hz, H-10); IR (film): n˜=2990, 2947, 2927,
2873, 1681.9, 1555, 1496, 1457, 1392, 1359, 1322, 1269, 1230, 1212,
1162, 1141, 1121, 1083, 1034, 998, 966, 941, 901 cm1; MS (CI)
calcd: 250.1569 [M+] , found: 250.1551; calcd: 251.1647 [M++H],
found: 251.1668.
2-DeoxyDHA 35, mp: 142–144 8C, was prepared by catalytic hydro-
genation of DHA as described.[2] 2-DeoxyDHA (500 mg, 1.87 mmol)
in CH2Cl2 (10 mL) under N2 was treated sequentially with methane-
sulfonyl chloride (0.35 mL, 2.24 mmol, 1.2 equiv) and triethylamine
(0.39 mL, 2.80 mmol, 1.5 equiv) at room temperature. After 1.5 h,
the mixture was treated with saturated NH4Cl (10 mL) and extract-
ed with CH2Cl2 (3R10 mL). The combined organic layer was dried
(MgSO4). Filtration and concentration of the filtrate under reduced
pressure left a pale-yellow residue, which on chromatography with
ethyl acetate/hexanes (15:85) gave the 2-deoxyglycal 19 (370 mg,
79%), identical with the sample obtained from Fe2+ decomposition
of DHA, and a second uncharacterized dimeric product (64.8 mg,
6.7%).
The tricarbonyl compound 18 was obtained as a single epimer
when it was freshly isolated: 1H NMR: d=1.095 (d, J=5.8 Hz, 3H,
3-Me), 1.17 (d, J=7.3 Hz, 3H, 1’’-Me), 1.48–1.68 (m, 4H), 1.71–1.96
(m, 4H), 2.13 (s, 3H, MeCO), 2.30–2.43 (m, 1H), 2.48–2.65 (m, 2H),
2.70–2.81 (m, 1H), 9.74 ppm (s, 1H, CHO). The characterization of
this compound is described elsewhere.[55]
Artesunate 3 :
a) FeSO4 : Compounds 3 (6.7 mg, 6%), 22 (53.3 mg, 46%), and 23
(25.7 mg, 22%) were obtained from FeSO4·7H2O (24.9 mg,
0.3 equiv) and 3 (115.2 mg, 0.3 mmol) in CH3CN/deionized H2O (1:1,
6 mL) followed by chromatography with ethyl acetate/hexanes
(25:75) containing 0.05% acetic acid. 22[9] colorless oil ; 1H NMR:
d=0.86 (d, J=7.0 Hz, 3H, 6-Me), 0.94 (d, J=6.2 Hz, 3H, 9-Me),
1.34–1.46 (m, 1H), 1.48–1.62 (m, 2H), 1.70–1.88 (m, 3H), 1.90–2.01
(m, 3H), 2.11 (s, 3H, MeCO), 2.30–2.41 (m, 2H), 2.30–2.72 (m, 4H),
3.92 (dd, J=7.9, 7.6 Hz, 1H), 4.27 (dd, J=9.7, 9.4 Hz, 1H), 5.81–5.84
(d, J=9.7 Hz, 1H), 6.20 ppm (s, 1H, H-12); 13C NMR: d=12.28,
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20.87, 21.85, 22.88, 27.94, 28.81, 29.28, 30.79, 34.18, 35.73, 47.55,
55.19, 69.12, 80.32, 91.21, 93.68, 168.74, 170.82, 176.48 ppm; MS
(ESI), m/z 407.1800 [M++Na], 430.2600 [M++2Na]; 23[9] colorless
oil ; 1H NMR: d=0.91 (d, J=6.2 Hz 3H, 9-Me), 0.99 (d, J=7.3 Hz,
3H, 6-Me), 1.15–1.62 (m, 8H), 1.59 (s, 3H, 3-Me), 1.75–1.95 (m, 3H),
2.49–2.59 (m, 1H), 2.61–2.71 (m, 4H), 3.49–3.58 (m, 1H), 5.27 (s,
1H, H-12), 5.75 ppm (d, J=7.0 Hz, 1H, H-10); 13C NMR: d=15.06,
18.90, 20.88, 22.97, 28.84, 29.59, 30.67, 30.83, 34.34, 35.33, 41.00,
41.72, 69.86, 82.89, 95.60, 95.93, 108.43, 171.72, 176.04 ppm; MS
(ESI), m/z calcd: 407.1682, found: 407.1683 [M++Na]; calcd:
267.1596, found: 267.1587 [M+ ACHTUNGTRENNUNG(CH2COOH)2] .
b) FeSO4–ascorbic acid : The above procedure was repeated with
ascorbic acid (52.8 mg, 0.3 mmol, 1.0 equiv) to provide 3 (2.7 mg,
2%), 22 (64.2 mg, 56%), and 23 (25.3 mg, 22%).
10-Deoxo-10-dihydroartemisinin 5 :
a) FeSO4 : From FeSO4·7H2O (33.2 mg, 0.3 equiv) and 5 (107.2 mg,
0.4 mmol) in CH3CN/deionized H2O (1:1, 8 mL) followed by chroma-
tography with ethyl acetate/hexanes (20:80) gave, in order of elu-
tion, 5 (3.2 mg, 3%), 26 (4.2 mg, 4%), 27 (2.2 mg, 2%), 25 (45 mg,
42%), and 24 (45 mg, 42%). 26[54,56] colorless oil ; 1H NMR: d=1.01
(d, J=6.7 Hz, 3H, 3-Me), 1.09 (d, J=6.2 Hz, 3H, 1’-Me), 1.36–1.60
(m, 3H), 1.74–2.11 (m, 5H), 2.14 (s, 3H, MeCO), 2.21–2.31 (m, 1H),
2.31–2.42 (m, 2H), 2.51–2.62 (m, 1H), 4.08 (dd, J=5.3, 5.6 Hz, 1H),
4.21 (dd, J=3.8, 3.8 Hz, 1H), 8.08 ppm (s, 1H, OCHO); 13C NMR:
d=15.54, 20.17, 20.55, 29.87, 30.18, 31.60, 34.65, 40.41, 41.25,
53.18, 56.86, 66.32, 160.87, 208.65, 211.96 ppm; MS (CI, NH3): m/z
268 [M+] (4%), 269 [MH+] (38%), 270 [MH+] 13C, (6%); C15H24O4
(268.4) anal. calcd: C 67.14, H 9.01, found: C 66.72, H 8.86%; 27,
colorless fine crystals, mp: 159.7–160.4 8C (158–160 8C[57]) ; 1H NMR:
d=0.78 (d, J=7.0 Hz, 3H), 0.98 (d, J=6.2 Hz, 3H), 1.36–1.84 (m,
5H), 1.59 (s, 3H), 1.87–1.96 (m, 3H), 2.04–2.18 (m, 3H), 3.38 (dd, J=
11.7, 11.7 Hz, 1H), 3.73 (dd, J=5.9, 5.6 Hz, 1H), 4.09–4.12 (m, 1H),
4.91 ppm (s, 1H); 25[9] colorless square prisms, mp: 193.7–194.6 8C;
1H NMR: d=0.89 (d, J=9.7 Hz, 3H), 0.91–0.93 (d, J=7.3 Hz, 3H),
1.00–1.05 (m, 1H), 1.56 (s, 3H), 1.21–1.60 (m, 5H), 1.71–1.81 (m,
2H), 1.86–1.99 (m, 2H), 2.24–2.35 (m, 1H), 3.30–3.35 (dd, J=5.0,
5.0 Hz, 1H), 3.54–3.55 (m, 1H), 3.89 (dd, J=6.6, 5.7 Hz 1H),
5.18 ppm (s, 1H); 13C NMR: d=16.64, 19.07, 20.97, 24.12, 26.77,
30.71, 34.71, 35.37, 40.15, 42.15, 64.97, 70.08, 83.55, 95.82,
107.60 ppm; IR (film): n˜=722, 818, 879, 932, 954, 980, 1019, 1030,
1044, 1058, 1084, 1107, 1151, 1226, 1263, 1282, 1374, 1386, 1455,
1734, 2842, 2872, 2881, 2945, 2956, 2999, 3535 cm1; MS (CI, CH4)
m/z 154 (30%), 208 (11%), 251 (100%), 252 (18%), 268 [M+] (4%),
269 [M++H] (36%); 24[9] colorless crystals, mp: 93.4–94.4 8C;
1H NMR: d=0.725 (d, J=7.2 Hz, 3H), 0.96 (d, J=6.0 Hz, 3H), 0.85–
1.09 (m, 1H), 1.33–1.40 (m, 1H), 1.49–1.86 (m, 5H), 1.91–2.00 (m,
2H), 2.12 (s, 3H), 2.40–2.51 (m, 1H), 3.54 (dd, J=5.9, 5.9 Hz, 1H),
3.72 (ddd, J=5.1, 5.1, 5.1 Hz, 1H), 3.92 (dd, J=8.3, 7.5 Hz, 1H), 4.26
(dd, J=7.9, 7.9 Hz, 1H), 5.97 ppm (s, 1H); 13C NMR: d=13.07,
20.96, 21.36, 21.96, 28.06, 30.03, 30.80, 35.65, 47.44, 55.91, 68.04,
69.02, 80.68, 93.05, 169.39 ppm; MS (CI, CH4) m/z 165 (6%), 209
(100%), 210 (16%), 251 (46%), 225 (15%), 267 [M+H] (50%), 268
[M+] (40%).
b) FeSO4–ascorbic acid : The above procedure was repeated with
ascorbic acid (70.4 mg, 0.4 mmol, 1.0 equiv) to provide 26 (6.3 mg,
6%), 25 (43 mg, 40%), and 24 (58 mg, 54%).
c) FeBr2 : From FeBr2 (21.6 mg, 0.5 equiv) and 5 (54.9 mg, 0.2 mmol)
in THF (2 mL) followed by chromatography with ethyl acetate/hex-
anes (30:70) gave, in order of elution, 28 (4.4 mg, 9%), unreacted 5
(1.8 mg, 3%), 26 (34.7 mg, 63%), 27 (4.7 mg, 9%), and 24 (7.1 mg,
13%). 26, colorless crystals, mp: 104–105 8C (102–104 8C[54]) ;
1H NMR: d=0.90 (d, J=6.0 Hz, 3H), 0.925 (d, J=7.6 Hz, 3H), 1.53
(s, 3H), 1.68–1.90 (m, 1H), 2.24–2.31 (m, 1H), 3.31 (dd, J=11.3,
4.4 Hz, 1H), 3.94–3.98 (dd, J=11.5, 6.8, Hz, 1H), 5.25 ppm (s, 1H);
13C NMR: d=16.67, 18.91, 22.14, 24.02, 24.06, 26.42, 34.47, 34.52,
35.33, 40.02, 45.88, 64.41, 82.49, 96.08, 107.14 ppm; MS (CI, NH3):
m/z 252 [M+] (8%), 253 [M+H+] (100%), 270 [M+NH4
+] (72%).
d) Fe ACHTUNGTRENNUNG(OAc)2 and 4-oxo-TEMPO : From Fe ACHTUNGTRENNUNG(OAc)2 (522.0 mg,
1.5 equiv), 5 (539.2 mg, 2.0 mmol), and 4-oxo-TEMPO (681.0 mg,
2.0 equiv) in CH3CN/CH2Cl2 (1:1, 16 mL) was obtained after chroma-
tography with ethyl acetate/hexanes (30:70), in order of elution, 5
(6.6 mg, 1%), 26 (106.8 mg, 20%), 24 (128.6 mg, 24%), N-hydroxy-
2,2,6,6-tetramethyl-1-piperidine (261.2 mg, 38%), and the radical-
trapped product 42 (26.9 mg, 3%). 42, colorless oil, 1H NMR: d=
0.78 (d, J=7.3 Hz, 3H), 0.86–0.94 (m, 1H), 0.94 (d, J=6.4 Hz, 3H),
1.02–1.23 (m, 3H), 1.16 (s, 3H), 1.17 (s, 3H), 1.24–1.35 (m, 1H), 1.29
(s, 3H), 1.32 (s, 3H), 1.40–1.51 (m, 1H), 1.53–1.67 (m, 5H), 1.81–1.86
(m, 1H), 2.12–2.28 (m, 1H), 2.14 (s, 3H), 2.32–2.42 (m, 1H), 2.55–
2.60 (m, 1H), 2.85 (s, 1H), 3.52 (dd, J=11.7, 11.7 Hz, 1H), 3.67–3.91
(m, 2H), 6.05 ppm (s 1H); 13C NMR: d=13.46, 21.14, 21.21, 21.87,
22.90, 23.00, 26.45, 28.84, 32.85, 33.14, 34.70, 35.76, 49.07, 51.18,
53.65, 53.70, 63.24, 63.31, 68.57, 72.85, 78.70, 92.12, 169.41,
208.21 ppm; IR (film): n˜=456, 467, 538, 601, 617, 666, 696, 736,
804, 847, 864, 919, 973, 1002, 1066, 1113, 1145, 1227, 1305, 1363,
1376, 1467, 1727, 1756, 2877, 2961, 3500 cm1; MS (CI, CH4) m/z
(%) 440 (3), 380 (45), 282 (52), 209 (100); MS (CI), calcd: 440.3012,
found: 440.3039 [M++H], calcd: 381.2879, found: 381.2822 [M+
OCOCH3], calcd: 380.2801, found: 380.2794 [M+HOCOCH3].
e) Fe ACHTUNGTRENNUNG(OAc)2 and 4-oxo-TEMPO mixed experiment : A solution of
Fe ACHTUNGTRENNUNG(OAc)2 (417.6 mg, 3.0 equiv), 5 (215.2 mg, 0.8 mmol), the 1,2,4-tri-
oxolane 13[51] (211.3 mg, 0.8 mmol), and 4-oxo-TEMPO (544.8 mg,
2.0 equiv) in CH3CN/CH2Cl2 (1:1, 12 mL) under N2 was stirred at
room temperature for 24 h. It was quenched with saturated aque-
ous sodium hydrogen carbonate (12 mL) followed by acetic acid
(3 mL). The aqueous layer was extracted with ethyl acetate (3R
24 mL). The organic layer was separated and washed with saturat-
ed aqueous NH4Cl (2R24 mL). Filtration and concentration of the
filtrate under reduced pressure gave a residue which was redis-
solved in ethyl acetate (2 mL). The organic layer was washed with
saturated aqueous sodium hydrogen carbonate (3R8 mL). The or-
ganic layer was separated as ’organic layer A’. The combined aque-
ous layer was acidified with 2m aqueous H2SO4. The acidified aque-
ous layer was extracted with ethyl acetate (3R60 mL). The com-
bined organic layer was dried (MgSO4). Filtration and concentration
of the latter under reduced pressure gave solely 44, a white solid
(196.3 mg, 73%), with data as previously described:[51] 1H NMR: d=
1.14 (s, 6H), 1.14–1.35 (m, 3H), 1.30 (s, 6H), 1.48–1.60 (m, 3H),
2.09–2.29 (m, 7H), 2.46–2.62 (m, 3H), 4.03–4.14 ppm (m, 1H). The
’organic layer A’ was submitted to chromatography with ethyl ace-
tate/hexanes (30:70) to give 5 (29.2 mg, 14%), 36 (27.3 mg, 13%),
24 (20.4 mg, 9%), N-hydroxy-2,2,6,6-tetramethyl-1-piperidine
(80.8 mg, 15%), and the radical-trapped product 42 (11.9 mg, 3%).
f) Thermolysis : N2 was slowly passed over neat crystalline 5
(100 mg, 0.37 mmol) in a round-bottom glass flask immersed in an
oil bath at 100 8C during 18 h. The resulting mixture was submitted
to chromatography with ethyl acetate/hexanes (30:70) to give 5
(17.4 mg, 17%) and 26 (56.2 mg, 56%). Heating for longer periods
resulted in formation of more complex product mixtures, evidently
arising from subsequent reactions of 26.
10-(4’-Fluorophenyl)-10-deoxy-10-dihydroartemisinin 6 :
a) FeSO4 : FeSO4·7H2O (24.9 mg, 0.3 equiv) in deionized H2O (3 mL)
was added dropwise to a stirred solution of 6 (108.6 mg, 0.3 mmol)
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in CH3CN (3 mL). The eluent for chromatography was ethyl ace-
tate/hexanes (20:80), which returned 6 (194 mg, 96%), 29 (~1 mg,
<1%), 31 (2.1 mg, 2%) and 30 (1 mg, 1%). 29 colorless oil,
1H NMR: d=0.44 (d, J=7.5 Hz, 3H), 0.99 (d, J=6.3 Hz, 3H), 1.21–
1.55 (m, 5H), 1.59–2.04 (m, 3H), 2.06 (s, 3H), 2.28–2.38 (m, 1H),
2.66–2.74 (m, 1H), 3.83–3.90 (m, 1H), 4.10–4.16 (m, 1H), 5.52 (d,
J=6.6 Hz, 1H, H-10), 6.26 (s, 1H, H-12), 6.94–7.02 (m, 2H, 2RPh-H),
7.20–7.27 ppm (m, 2H, 2RPh-H); 13C NMR: d=12.87, 20.80, 22.13,
27.67, 31.51, 33.14, 35.56, 37.92, 39.64, 45.35, 53.13, 55.50, 57.34,
68.78, 72.93, 81.96, 92.51, 102.65, 114.82 (d, JCF=20.93 Hz, Ph),
127.61 ppm (d, JCF=7.73 Hz, Ph);
19F NMR (282 MHz, CDCl3): d=
116.76 ppm; MS (CI, CH4): m/z 275 (100%), 317 (81%), 361 [M+
H] (19%), 391 (23%); MS (CI), m/z (%) calcd: 362.1893, found:
362.1866 [M++H] (25), calcd: 361.1815, found: 361.1830 [M+]
(100); 31, colorless oil, 1H NMR: d=1.00 (d, J=6.6 Hz, 3H), 1.03 (d,
J=6.0 Hz, 3H), 1.37–1.60 (m, 5H), 1.73–1.88 (m, 5H), 2.15 (s, 3H),
2.22–2.57 (m, 1H), 2.50–2.61 (m, 1H), 6.07 (d, J=6.0 Hz, 1H, H-10),
6.96–7.02 (m, 2H, 2RPh-H), 7.08–7.22 (m, 2H, 2RPh-H), 8.10 ppm
(s, 1H, CHO); 13C NMR: d=12.29, 20.47, 20.85, 30.06, 30.24, 31.49,
35.01, 39.64, 40.66, 41.67, 53.01, 57.32, 76.55, 115.57 (d, JCF=
21.45 Hz, Ph), 128.16 (d, JCF=7.95 Hz, Ph), 135.55 (d, JCF=3.15 Hz,
Ph), 160.57 (d, JCF=19.73 Hz, Ph), 163.96, 208.98, 212.54 ppm;
19F NMR (300 MHz, CDCl3): d=114.42 ppm; MS (CI, CH4): m/z 182
(26%), 317 (100%), 318 (32%), 357 (24%), 361 [M+H] (15%), 391
(8%); MS (CI), m/z (%) calcd: 316.1839, found: 316.1838 [M+
HCOOH2] (25); calcd: 317.1917, found: 317.1917 [M+HCOOH]
(100); 30, colorless oil, 1H NMR: d=0.44 (d, J=7.8 Hz, 3H), 0.92 (d,
J=6.0 Hz, 3H), 0.98–1.07 (m, 1H), 1.25–1.57 (m, 4H), 1.61 (s, 3H),
1.72–1.84 (m, 3H), 1.96–2.15 (m, 3H), 2.48–2.56 (m, 1H), 3.59 (m,
1H), 5.22 (d, J=7.5 Hz, 1H, H-10), 5.38 (s, 1H, H-12), 6.95–7.01 (m,
2H, 2RPh-H), 7.15–7.20 ppm (m, 2H, 2RPh-H); 13C NMR: d=14.66,
19.01, 20.76, 25.51, 30.09, 30.87, 31.13, 34.80, 35.72, 38.14, 40.58,
41.58, 52.61, 70.15, 71.08, 83.34, 97.14, 107.48, 114.88 (d, JCF=
21.15 Hz, Ph), 128.15 ppm (d, JCF=8.03 Hz, Ph);
19F NMR (282 MHz,
CDCl3): d=116.46 ppm; MS (CI, CH4): m/z (%)=391 (8), 363 (54),
345 (53), 317 (62), 267 (100).
b) FeSO4–ascorbic acid : The above procedure was repeated with
ascorbic acid (52.8 mg, 0.3 mmol, 1.0 equiv) to provide 6 (190 mg,
94%), 29 (~1 mg, <1%), and 30 (4 mg, 4%).
c) FeBr2 : From FeBr2 (21.6 mg, 0.5 equiv) and 6 (73.5 mg, 0.2 mmol)
in THF (2 mL) after chromatography with ethyl acetate/hexanes
(20:80) gave, in order of elution, 29 (10.2 mg, 14%), 31 (12.4 mg,
17%), and another unidentified product (3.3 mg, 5%) as a colorless
oil : 1H NMR: d=1.00 (d, J=1.5 Hz, 3H), 1.02 (d, J=8.2 Hz, 3H),
1.18–1.31 (m, 1H), 1.45–1.65 (m, 6H), 1.78–1.86 (m, 1H), 2.08–2.31
(m, 2H), 2.10 (s, 3H), 2.48–2.65 (m, 1H), 4.52 (d, J=9.7 Hz, 1H),
7.00–7.06 (m, 2H), 7.25–7.30 ppm (m, 2H); MS (CI, CH4): m/z (%)
317 (100), 259 (46), 180 (42); MS (ESI), m/z calcd: 317.1917, found:
317.1922 [M++H].
Artemisone 7:
a) FeSO4 : From FeSO4·7H2O (24.9 mg, 0.3 equiv) and 7 (120.3 mg,
0.3 mmol) in CH3CN/deionized H2O (1:1, 6 mL) followed by chroma-
tography with ethyl acetate/hexanes (50:50) gave, in order of elu-
tion, 20 (10.7 mg, 16%), 18[9] (3.4 mg, 5%), unreacted 7 (17.4 mg,
14%), and 33 (34 mg, 28%). 20[9] colorless oil ; 1H NMR: d=0.95 (d,
J=6.0 Hz, 3H), 1.17 (d, J=7.2 Hz, 3H), 1.44–1.50 (m, 2H), 1.66–1.77
(m, 3H), 1.92–2.13 (m, 3H), 2.39–2.43 (m, 2H), 3.93–3.97 (m, 1H),
4.10–4.14 (m, 1H), 9.55–9.56 (d, J=2.4 Hz, 1H), 9.94 (s, 1H); 18[55]
pale-yellow viscous oil ; 1H NMR: d=1.09 (d, J=7.0 Hz, 3H), 1.48–
1.65 (m, 1H), 1.69–1.82 (m, 1H), 1.84–1.94 (m, 1H), 2.01–2.18 (m,
1H), 2.13 (s, 3H), 2.30–2.43 (m, 1H), 2.50–2.62 (m, 1H), 2.67–2.81
(m, 1H), 9.73 ppm (s, 1H); 33 colorless oil ; 1H NMR: d=0.84 (d, J=
7.0 Hz, 3H, 9-Me), 0.89 (d, J=6.2 Hz, 3H, 6-Me), 0.95–0.97 (m, 1H),
1.05–1.30 (m, 3H), 1.37–1.62 (m, 2H), 1.52 (s, 3H, 3-Me), 1.77–1.96
(m, 2H), 2.12–2.33 (m, 2H), 2.44–2.54 (m, 1H), 3.00–3.18 (m, 4H),
3.24–3.42 (m, 4H), 3.55 (d, J=2.6 Hz, 1H), 4.21–4.25 (d, J=10.3 Hz,
1H, H-10), 5.28 ppm (s, 1H, H-12); 13C NMR: d=14.59, 19.13, 21.68,
22.84, 28.29, 30.64, 34.59, 35.29, 42.32, 42.46, 47.01, 52.37, 69.77,
83.62, 93.49, 96.01, 108.39 ppm; IR (film): n˜=451, 467, 515, 535,
667, 734, 799, 811, 855, 875, 921, 944, 979, 1016, 1077, 1125, 1220,
1275, 1305, 1383, 1453, 1645, 2875, 2932, 3500 cm1; MS (CI, CH4):
m/z (%) 402 (100), 267 (75), 175 (79); MS (ESI), m/z calcd: 402.1950,
found: 402.1951 [M++H], calcd: 267.1596, found: 267.1604 [M+
4-(S,S-dioxo)thiomorpholin-1-yl] .
b) FeSO4–ascorbic acid : Repetition of the above procedure with
ascorbic acid (52.8 mg, 0.3 mmol, 1.0 equiv) gave 20 (9.4 mg, 14%),
18 (4.4 mg, 6%), 7 (4.2 mg, 3%), and 33 (24.2 mg, 20%).
c) FeBr2 : Compounds 18 (64.6 mg, 22%), 20 (80.4 mg, 29%), and
34 (41.7 mg, 9%) were obtained from FeBr2 (269.6 mg, 0.5 equiv)
and 7 (501.3 mg, 1.25 mmol) in THF (12 mL) after chromatography
with ethyl acetate/hexanes (40:60). 34 colorless rectangular plates,
mp: 192–193 8C; [a]22D =126 (c=0.66, CHCl3) ; 1H NMR: d=0.85 (d,
J=7.0 Hz, 3H, 9-Me), 0.92 (d, J=5.9 Hz, 3H, 6-Me), 1.01–1.38 (m,
5H), 1.49 (s, 3H, 3-Me), 1.52–1.61 (m, 2H), 1.66–1.73 (m, 2H), 1.75–
1.90 (m, 2H), 2.43–2.55 (m, 1H), 3.01–3.21 (m, 4H), 3.26–3.42 (m,
4H), 4.21–4.25 (d, J=10.6 Hz, 1H, H-10), 5.32 ppm (s, 1H, H-12);
13C NMR: d=14.84, 19.32, 22.41, 22.81, 25.12, 28.21, 34.66, 34.87,
35.60, 42.71, 46.56, 47.12, 52.38, 82.90, 93.77, 96.80, 108.49 ppm; IR
(film): n˜=414, 428, 432, 445, 453, 471, 872, 973, 1009, 1073, 1125,
1141, 1206, 1277, 1304, 1383, 2873, 2929 cm1; MS (CI), m/z (%)
calcd: 386.2001, found: 386.2005 [M++H] (100).
d) Fe ACHTUNGTRENNUNG(OAc)2 and 4-oxo-TEMPO : From Fe ACHTUNGTRENNUNG(OAc)2 (339.3 mg,
1.5 equiv), 7 (521.9 mg, 1.3 mmol), and 4-oxo-TEMPO (442.7 mg,
2.0 equiv) in CH3CN/CH2Cl2 (1:1, 16 mL) was obtained after chroma-
tography with ethyl acetate/hexanes (50:50), in order of elution, 32
(60.0 mg, 12%), 20 (31.6 mg, 11%), 33 (40.0 mg, 8%), 18 (10.1 mg,
3%), 43 (69 mg, 10%), and N-hydroxy-2,2,6,6-tetramethyl-1-piperi-
dine (303 mg, 7%). 32 colorless plates, mp: 120.4–121.2 8C;
1H NMR: d=0.80 (d, J=7.3 Hz, 3H), 0.94 (d, J=6.4 Hz, 3H), 0.99–
1.09 (m, 1H), 1.24–1.30 (m, 1H), 1.32–1.40 (m, 1H), 1.44–1.62 (m,
2H), 1.73–1.86 (m, 2H), 1.90–1.97 (m, 2H), 2.12 (s, 3H), 2.32–2.42
(m, 1H), 2.98–3.15 (m, 4H), 3.30–3.45 (m, 4H), 3.84–3.92 (m, 1H),
4.19–4.24 (dd, J=7.6, 7.6 Hz, 1H), 4.29–4.32 (d, J=10.5 Hz, 1H),
5.93 ppm (s, 1H); 13C NMR: d=13.41, 20.88, 21.95, 22.55, 27.92,
30.89, 31.86, 35.76, 47.13, 48.03, 52.39, 55.21, 68.88, 80.11, 92.35,
93.69, 169.60 ppm; IR (film): n˜=450, 466, 471, 595, 666, 734, 793,
857, 879, 917, 946, 998, 1033, 1080, 1125, 1227, 1272, 1306, 1368,
1456, 1639, 1752, 2933 cm1; MS (ESI) m/z calcd: 402.1950, found:
402.1983 [M++H], calcd: 267.1596, found: 267.1622 [M+4’-(S,S-di-
oxo)thiomorpholin-1’-yl] ; 43 colorless foam; [a]22D =17.58 (c=0.7,
CHCl3) ;
1H NMR: d=0.84–0.86 (d, J=7.3 Hz, 3H, 9-Me), 1.02–1.05
(d, J=6.2 Hz, 3H, 6-Me), 1.11 (s, 3H, Me, 4’’-oxotetramethylpiperi-
dinyl), 1.13 (s, 3H, Me, 4’’-oxotetramethylpiperidinyl), 1.27 (s, 3H,
Me, oxotetramethylpiperidinyl), 1.31 (s, 3H, Me, 4’’-oxotetramethyl-
piperidinyl), 1.38–1.41 (m, 1H, H-8a), 1.42–1.52 (m, 2H, H-5), 1.58–
2.10 (m, 7H, H-8, H-5a, H-6, H-7, H-9), 2.15–2.22 (m, 2H, CH2), 2.56–
2.61 (m, 2H, CH2), 3.10–3.11 (m, 4H, H2’, 4’-(S,S-dioxo)thiomorpho-
lin-1’-yl), 3.31–3.34 (m, 4H, H3’, 4’-(S,S-dioxo)thiomorpholin-1’-yl),
3.80–3.88 (m, 1H, OCH2), 3.93–4.0 (m, 1H, OCH2), 4.63–4.64 (d, J=
3.5 Hz, 1H, H-10), 10.07 ppm (s, 1H, CHO); 13C NMR: d=15.43 (C9-
Me), 20.80 (C6-Me), 21.59 (C8/C7/C5), 22.68 (Me, 4’’-oxotetramethyl-
piperidinyl), 22.78 (Me, 4’’-oxotetramethylpiperidinyl), 28.63 (C5/C7/
C8), 32.86 (Me, 4’’-oxotetramethylpiperidinyl), 33.0 (Me, 4’’-oxote-
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tramethylpiperidinyl), 34.46 (C6/C9), 36.44 (C7/C5/C8), 38.48 (C9/
C6), 47.07 (C2’, 4’-(S,S-dioxo)-thiomorpholin-1’-yl), 50.69 (C8a/C5a),
52.28 (C3’, 4’-(S,S-dioxo)thiomorpholin-1’-yl), 53.53 (C5a/C8a), 53.64
(2RC, CH2, 4’’-oxotetramethylpiperidinyl), 63.09 (CMe2, 4’’-oxotetra-
methylpiperidinyl), 63.16 (CMe2, 4’’-oxotetramethylpiperidinyl),
76.73 (OCH2), 90.42 (C12a), 103.78 (C10), 207.26 (C12), 208.62 ppm
(C=O, 4’’-oxotetramethylpiperidinyl) ; IR (film): n˜=457, 463, 471,
557, 666, 707, 736, 782, 803, 857, 904, 993, 1031, 1081, 1126, 1149,
1194, 1230, 1272, 1306, 1363, 1378, 1414, 1455, 1722, 2877,
2932 cm1; MS (CI) calcd: 513.2998 [M++H], found: 513.2997.
10-(4’-Benzyl-1’-piperazinyl)-10-deoxo-10-dihydroartemisinin 8 :
a) FeSO4 : Unchanged compound 8 (42 mg, 96%) and products 20
(3%), and 18 (~0.5 mg, 1%) were obtained from FeSO4·7H2O
(8.3 mg, 0.3 equiv) and 8 (44.2 mg, 0.1 mmol) in CH3CN/deionized
H2O (1:1, 3 mL) followed by chromatography with ethyl acetate/
hexanes (40:60).
b) FeSO4–ascorbic acid : Repetition of the above procedure with
ascorbic acid (17.6 mg, 0.1 mmol, 1.0 equiv) gave, after column
chromatography with ethyl acetate/hexanes (40:60), 8 (12.7 mg,
29%), 20 (6.0 mg, 27%), and 18 (2.8 mg, 12%).
c) FeBr2 : From FeBr2 (118.6 mg, 0.5 equiv) and 8 (486.2 mg,
1.10 mmol) in THF (12 mL) was obtained after chromatography
with ethyl acetate/hexanes (40:60) 18 (12.5 mg, 5%), 20 (64.5 mg,
26%), and 35 (70 mg, 24%). 35 white needles, mp: 142–144 8C
(mp: 142–1438[2]) ; 1H NMR: d=0.90 (d, J=5.9 Hz, 3H, 9-Me), 1.01
(d, J=7.3 Hz, 3H, 6-Me), 1.14–1.32 (m, 5H), 1.54 (s, 3H, 3-Me),
1.48–1.60 (m, 1H), 1.68–1.75 (m, 3H), 1.77–1.88 (m, 2H), 2.16–2.26
(m, 1H), 2.71 (d, J=7.3 Hz, 1H), 4.78 (d, J=6.5 Hz, 1H, H-10),
5.34 ppm (s, 1H, H-12); MS (CI, NH3) m/z 251 [M
+OH] (100%),
267 [M+H] (46%). The compound was identical to a sample pre-
pared by catalytic hydrogenation of DHA according to the litera-
ture procedure.[2]
10-[4’-(2’’-Pyrimidyl)-1’-piperazinyl]-10-deoxo-10-dihydroartemisinin 9 :
a) FeSO4 : Unchanged compound 9 (42 mg, 97%) and the products
20 (~0.5 mg, 2%) and 18 (~0.3 mg, 1%) were obtained from
FeSO4·7H2O (8.3 mg, 0.3 equiv) and 9 (43.0 mg, 0.1 mmol) in
CH3CN/deionized H2O (1:1, 3 mL) followed by chromatography
with ethyl acetate/hexanes (40:60).
b) FeSO4–ascorbic acid : Repetition of the above procedure with
ascorbic acid (17.6 mg, 0.1 mmol, 1.0 equiv) gave, after chromatog-
raphy with ethyl acetate/hexanes (40:60), unchanged 9 (29.2 mg,
68%) and the products 20 (2.8 mg, 12%) and 18 (0.6 mg, 2.5%).
10-(Sulfamido)-10-deoxo-10-dihydroartemisinin 10 :
a) FeSO4 : From FeSO4·7H2O (24.9 mg, 0.3 equiv) and 10 (108.6 mg,
0.3 mmol) in CH3CN/deionized H2O (1:1, 6 mL) in CH3CN (3 mL) fol-
lowed by chromatography with ethyl acetate/hexanes (40:60) was
obtained, in order of elution, unreacted 10 (52 mg, 48%), 18
(1.3 mg, 2%), and 36 (9 mg, 8%). 36 pale-yellow oil ; 1H NMR: d=
0.94–0.96 (d, 3H, 9-Me, J=7.0 Hz), 0.98 (d, J=5.9 Hz, 3H, 6-Me),
1.23–1.39 (m, 3H), 1.40 (s, 3H, 3-Me), 1.55–1.83 (m, 5H), 1.87–1.96
(m, 1H), 2.00–2.08 (m, 1H), 2.32–2.45 (m, 1H), 3.73–3.76 (m, 1H),
4.82 (dd, J=10.3, 10.3 Hz, 1H, H-10), 4.87 (s, 2H, NH2), 5.15–5.18 (d,
J=10.6 Hz, 1H, NH), 5.38 ppm (s, 1H, H-12); IR (film): n˜=827, 882,
926, 1006, 1030, 1052, 1098, 1159, 1356, 1458, 1637, 2927, 3283,
3366, 3567 cm1; MS (ESI), m/z (%) calcd: 629.3108, found:
629.2918 [2M++H)], calcd: 267.1596, found: 267.1613 [M+SO2-
ACHTUNGTRENNUNG(NH2)2] .
c) FeBr2 : Compound 18 (107.3 mg, 32%) was obtained from FeBr2
(151.2 mg, 0.5 equiv) and 9 (506.8 mg, 1.40 mmol) in THF (12 mL)
after chromatography with ethyl acetate/hexanes (40:60). The reac-
tion was repeated with FeBr2 (15.5 mg, 0.2 equiv) and 10
(109.8 mg, 0.3 mmol) in THF (3 mL). The mixture was quenched
with brine and worked up according to the general method to
leave a residue, a solution which in chloroform deposited colorless
needles of sulfamide (18.4 mg, 63%), mp: 88.1–89.1 8C; 1H NMR
([D6]acetone): d=1.95–2.15 ppm (m, 4H, -NH2); MS (CI, CH4) m/z
(%) 80 (18) [M+NH2], 96 (22) [M+] , 97 (100) [MH+] , identical with
data from an authentic sample (Aldrich).
10-(4’-Fluorophenylamino)-10-deoxo-10-dihydroartemisinin 11:
a) FeSO4 : Compounds 11 (68.6 mg, 61%) and 37 (30.8 mg, 27%)
were obtained from FeSO4·7H2O (24.9 mg, 0.3 equiv) and 11
(113.1 mg, 0.3 mmol) in deionized H2O/CH3CN (1:1, 6 mL) after
chromatography with ethyl acetate/hexanes (30:70). 37 pale-
yellow oil ; [a]22D =138 (c=1.97, CHCl3) ; 1H NMR: d=0.89 (d, J=
6.4 Hz, 3H, 9-Me), 1.02 (d, J=7.0 Hz, 3H, 6-Me), 1.19–1.35 (m, 1H),
1.40–1.51 (m, 2H), 1.55 (s, 3H, 3-Me), 1.71–1.98 (m, 5H), 2.01–2.12
(m, 1H), 2.27–2.37 (m, 1H), 2.50–2.63 (m, 1H), 3.49 (s, NH), 3.58 (s,
1H), 4.75–4.78 (d, J=7.9 Hz, 1H, H-10), 5.27 (s, 1H, H-12), 6.66–6.70
(m, 2H, ArH), 6.84–6.92 ppm (m, 2H, ArH); IR (film): n˜=544, 737,
824, 885, 920, 975, 1014, 1080, 1147, 1219, 1271, 1385, 1456, 1515,
1614, 1705, 2931, 3428 cm1; MS (CI, CH4) m/z (%) 111 (4), 151 (62),
179 (6), 249 (14), 267 (62), 267 (12), 360 (30), 377 (100) [M+] , 378
(92) [M++H]; MS (ESI), m/z calcd: 378.2081, found: 378.2058 [M+
+H], calcd: 267.1596, found: 267.1596 [M+NHACHTUNGTRENNUNG(C6H6)F].
c) FeBr2 : Compounds 18 (75.4 mg, 24%) and 38 (53.7 mg, 12%)
were obtained from FeBr2 (140.2 mg, 0.5 equiv) and 11 (490.1 mg,
1.30 mmol) in THF (12 mL) after chromatography with ethyl ace-
tate/hexanes (30:70). 38 pale-yellow–orange oil ; [a]22D =445 (c=
1.24, CHCl3) ;
1H NMR: d=0.89 (d, J=5.9 Hz, 3H, 6-Me), 1.04–1.28
(m, 5H), 1.42 (s, 3H, 3-Me), 1.58–1.72 (m, 4H), 1.81 (d, J=1.5 Hz,
3H, 9-Me), 1.84–1.92 (m, 1H), 1.97–2.03 (m, 1H), 5.18 (d, J=1.2 Hz,
1H, H-12), 5.89 (br s, 1H, H-10), 6.94–6.95 ppm (m, 4H, ArH);
13C NMR: d=18.95 (C14), 19.64 (C15), 22.10 (C7), 24.84 (C13), 26.67
(C8), 34.64 (C5), 35.47 (C6), 35.49 (C4), 43.25 (C5a), 46.87 (C8a),
85.19 (C12), 87.90 (C12a), 107.01 (C3), 115.74 (d, JC,F=22.2 Hz,
ArC3’), 116.39 (d, JC,F=7.5 Hz, ArC2’), 119.42 (C9), 120.81 (C10),
142.70 (ArC1’), 157.45 ppm (d, JC,F=237.5 Hz, ArC4’) ; IR (film): n˜=
460, 463, 467, 471, 475, 479, 783, 823, 867, 963, 1186, 1206, 1223,
1384, 1403, 1509, 2873, 2927 cm1; MS (CI, NH3): m/z (%) 344 (84)
[MH+] , 343 (100) [M+] ; MS (ESI), m/z 344.2103 [M++H].
The enamine 38 (326.9 mg, 0.95 mmol) and sodium periodate
(835.8 mg, 4.1 equiv) were stirred in CCl4 (4 mL). CH3CN (4 mL) was
added followed by H2O (6 mL). The resulting mixture was stirred at
0 8C while ruthenium ACHTUNGTRENNUNG(III) chloride hydrate (4.4 mg, 0.022 equiv) was
added slowly. After 3 h, the reaction mixture was poured into
CH2Cl2 (20 mL). The aqueous layer was separated and extracted
with CH2Cl2 (3R15 mL). The combined organic layer was dried
(MgSO4). Filtration and concentration of the filtrate under reduced
pressure gave a deep-brown residue that on chromatography with
ethyl acetate/hexanes (40:60) gave the product 41 as a pale-yellow
gum (22.0 mg, 6%); [a]22D =128 (c=2.40, CHCl3) ; 1H NMR: d=0.96
(d, J=5.6 Hz, 3H, 6-Me), 1.13–1.32 (m, 5H), 1.40 (s, 3H, 3-Me),
1.52–1.74 (m, 2H), 1.59 (s, 3H, 9-Me), 1.80–1.84 (m, 1H), 1.87–1.95
(m, 1H), 1.98–2.05 (m, 1H), 2.24–2.30 (m, 1H), 5.35 (s, 1H, H-12),
5.54 (br s, 1H, 9-OH), 7.07–7.13 (m, 2H, ArH), 7.19–7.24 ppm (m,
2H, ArH); 13C NMR: d=18.88 (C14), 22.17 (C7), 23.86 (C15), 25.07
(C13), 26.52 (C8), 33.74 (C5), 34.43 (C4), 35.88 (C6), 46.02 (C5a),
47.27 (C8a), 73.38 (C9), 84.80 (C12a), 88.24 (C12), 108.77 (C3),
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116.46 (d, JC,F=22.5 Hz, ArC3’), 130.43 (C2’, JC,F=8.6 Hz, ArC2’),
136.00 (d, JC,F=3.2 Hz, C1’), 162.04 (d, JC,F=246.4 Hz, ArC4’),
170.39 ppm (C10); IR (KBr): n˜=542, 816, 864, 955, 996, 1020, 1141,
1147, 1215, 1233, 1417, 1509, 1677, 2882, 2923, 2933, 2952,
3422 cm1 (H-bonded OH); MS (CI), m/z calcd: 376.1924, found:
376.1941 [M++H] (100).
d) Fe ACHTUNGTRENNUNG(OAc)2 and 4-oxo-TEMPO : From Fe ACHTUNGTRENNUNG(OAc)2 (391.5 mg,
1.5 equiv), 11 (567.2 mg, 1.5 mmol), and 4-oxo-TEMPO (510.5 mg,
2.0 equiv) in CH3CN/CH2Cl2 (1:1, 16 mL) was obtained, after chro-
matography with ethyl acetate/hexanes (30:70) in order of elution,
11 (346.6 mg, 61%), 37 (13.8 mg, 2%), 38 (3.4 mg, 1%), and N-hy-
droxy-2,2,6,6-tetramethyl-1-piperidine (328.4 mg, 64%).
10-(4’-Fluorobenzylamino)-10-deoxo-10-dihydroartemisinin 12 :
c) FeBr2 : Compounds 18 (23 mg, 8%), 40 (110.5 mg, 24%), and 39
(23.9 mg, 5%) were obtained from FeBr2 (138.3 mg, 0.5 equiv) and
12 (500.5 mg, 1.28 mmol) in THF (12 mL) after chromatography
with ethyl acetate/hexanes (30:70). 40 pale-orange oil ; [a]22D =116
(c=1.39, CHCl3) ;
1H NMR: d=0.87 (d, J=5.6 Hz, 3H, 6-Me), 1.00–
1.39 (m, 5H), 1.42 (s, 3H, 3-Me), 1.65 (d, J=1.2 Hz, 3H, 9-Me), 1.50–
1.81 (m, 4H), 1.87–1.93 (m, 1H), 2.22–2.32 (m, 1H), 4.00 (d, J=
15.2 Hz, 1H, ArCH), 4.26 (d, J=15.2 Hz, 1H, ArCH), 4.91 (s, 1H, H-
12), 5.48 (br s, 1H, H-10), 6.95–7.01 (m, 2H, ArH), 7.21–7.26 ppm (m,
2H, ArH); 13C NMR: d=19.07 (C14), 19.11 (C15), 21.91 (C7), 24.84
(C13), 25.87 (C8), 34.91 (C5), 35.57 (C4, C6), 43.10 (C5a), 46.97 (C8a),
53.55 (ArCH), 85.44 (C12), 85.61 (C12a), 106.19 (C3), 108.98 (C9),
115.30 (d, JC,F=21.3 Hz, ArC3’), 125.42 (C10), 129.47 (d, JC,F=8.1 Hz,
ArC2’), 135.46 (d, JC,F=3.2 Hz, ArC1’), 162.02 ppm (d, JC,F=243.6 Hz,
ArC4’) ; IR (film): n˜=464, 467, 471, 475, 854, 878, 958, 1150, 1221,
1384, 1509, 1604, 1682, 2874, 2926 cm1; MS (CI, NH3) m/z (%) 358
(56) [MH+] , 357 (100) [M+] ; MS (ESI), m/z (%) calcd: 358.2182,
found: 358.1975 [M++H]; 39 yellow oil ; [a]22D =84 (c=0.72,
CHCl3) ;
1H NMR: d=0.89 (d, J=6.2 Hz, 3H, 9-Me), 0.98 (d, J=
7.3 Hz, 3H, 6-Me), 1.06–1.46 (m, 5H), 1.52 (s, 3H, 3-Me), 1.73–1.93
(m, 5H), 2.10–2.37 (m, 2H), 3.49–3.53 (m, 1H), 3.84 (d, J=13.5 Hz,
1H, ArCH), 4.06 (d, J=14.1 Hz, 1H, ArCH), 4.09 (d, 1H, H-10), 5.28
(s, 1H, H-12), 6.94–7.00 (m, 2H, ArH), 7.29–7.35 ppm (m, 2H, ArH);
IR (film): n˜=481, 826, 885, 972, 1083, 1154, 1221, 1384, 1458, 1509,
1604, 1670, 2875, 2930, 3446 cm1; MS (ESI), m/z (%) calcd:
392.2237, found: 392.2141 [M++H].
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